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Abstract
Variegate porphyria (VP, MIM 176200) is a low penetrance autosomal dominant
disorder that stems from mutations in the protoporphyrinogen oxidase (PPOX) gene.
VP is found in most populations, but has a high prevalence in the South African
Afrikaner population with most patients inheriting the same PPOX mutation (R59W)
from a common ancestor. The clinical manifestations of the disease include acute
neurovisceral attacks and/or cutaneous photosensitivity. Great variation in the clinical
presentation of VP is observed; even in members of the same family that share a
common genetic background and that have been exposed to similar environmental
factors.
Candidate genes that may have an influence on phenotypic variation due to the
regulatory function in the haem biosynthetic pathway include the two delta-
aminolevulinic acid synthase (ALAS) genes and the porphobilinogen deaminase
(PBGD) gene. Sequence homology searches between different species indicated that
the ALAS-1, ALAS-2 and PBGD genes are highly conserved, indicating that these
genes have an important function to fulfill in the haem biosynthetic pathway.
The study population of 25 R59W individuals were divided in four categories according
to their clinical presentation. The distribution of clinical symptoms observed in this study
corresponds with results from previous studies.
Conformation sensitive gel electrophoresis (CSGE), conventional single stranded
conformation polymorphism analysis (SSCP) and two buffer SSCP analysis were
implemented to screen for possible sequence variants. The exons of all three genes as
well as the adjacent intronic sequences were investigated. A total of six sequence
variation sites were identified of which five had previously been described single
nucleotide polymorphisms (ALAS-1: 4713 T>C; PBGD: -64 C>T, 3581 A>G, 6479 G>T,
7064 C>A)] and a novel 8bp deletion (PBGD: 4582_ 4589del). No sequence variant was
identified in the ALAS-2 gene.
The CSGE method proved to have the highest sensitivity (83%), identifying five of six
sequence variant sites. The conventional SSCP method identified only three (50%)
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sequence variant sites, while the two buffer system detected two (33%) of the sequence
variants.
The 4713 T>C SNP in exon 4 of the ALAS-1 gene and the -64 C>T SNP in the PBGD
gene were selected for further investigation due to their location in the respective
genes. These sequence variants were typed in 50 patients and 50 control subjects
matched for ethnic background. The relationship between variation at these loci and
clinical features was investigated. No statistical significant association was observed
for either of the 4713 T>C SNP (P= 0.717) or the -64 C>T SNP (P= 0.931).
Genetic modifying factors make a variable contribution to the total clinical picture and
are difficult to identify in small populations. Due to the fact that we only had a limited
number of VP samples, association cannot be ruled out. This study does, however,
provide insight into investigational approaches that should be undertaken in future
research concerning the ALAS and PBGD genes. Further knowledge concerning the
haem biosynthetic pathway could ultimately lead to the understanding and assessment
of the clinical expression observed in individuals with VP.
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Opsomming
Variegate porfirie (VP, MIM 176200) is 'n lae penetrasie outosomaal dominante siekte
wat veroorsaak word deur mutasies in die protoporfirienogeen oksidase (PPOX) geen.
VP word gevind in die meeste populasies, maar het 'n hoë voorkoms in die Suid-
Afrikaanse populasie waar meeste pasiente dieselfde PPOX mutasie (R59W) van 'n
gemeenskaplike voorouer oorgeërf het. VP word gekenmerk deur akute neuroviserale
aanvalle en/of fotosensitiewe vel. Groot variasie word egter waargeneem in die kliniese
uitdrukking van VP, selfs in lede van dieselfde familie wat 'n gemeenskaplike genetiese
agtergrond deel en wat blootgestel is aan dieselfde omgewingsfaktore.
Kandidaat gene wat as gevolg van hulle regulatoriese funksie in die heem biosintetiese
padweg 'n effek op die ekspressie van VP mag hê, sluit in die twee delta-
aminolevuliniese suur sintase (ALAS) en die porfobilinogeen deaminase (PBGD) gene.
Homologie ondersoeke van die ALAS-1, ALAS-2 en PBGD gene in verskillende spesies
dui daarop dat die gene hoogs gekonserveerd is en dus gevolglik 'n belangrike funksie
in die heem biosintetiese padweg vertolk.
Die studie populasie van 25 R59W individue is verdeel in vier kategorieë op grond van
hulle kliniese simptome. Die verspreiding van die kliniese simptome wat waargeneem
is tydens hierdie studie stem ooreen met die resultate van vorige studies.
Konformasie sensitiewe gel elektroforese (CSGE), konvensionele enkelstring
konformasie polimorfisme analise (SSCP) en twee buffer SSCP analise is gebruik vir
die identifisering van genetiese variasie. Die eksons van al drie gene, sowel as die
aangrensende intron volgordes, is ondersoek. 'n Totaal van ses areas van genetiese
variasie is geïdentifiseer, waarvan vyf reeds beskryfde polimorfismes is (ALAS-1: 4713
T>C; PBGD: -64 C>T, 3581 A>G, 6479 G>T, 7064 C>A) en 'n nuwe 8bp delesie
(PBGD: 4582_ 4589del). Geen genetiese volgorde variasie is gevind in die ALAS-2
geen nie.
Die CSGE metode het die hoogste sensitiwiteit getoon (83%) en het vyf van die ses
volgorde variasies geïdentifiseer. Die konvensionele SSCP metode het slegs drie
volgorde variasies geïdentifiseer (50%), terwyl die twee buffer deteksie-sisteem twee
variasies geïdentifiseer (33%) het.
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Die 4713 T>C polimorfisme in ekson 4 van die ALAS-1 geen en die -64 C>T
polimorfisme in die PBGD geen, is geselekteer vir verdere ondersoek as gevolg van
hulle posisie in die respektiewe gene. Die volgorde variasies is getipeer in 50 R59W
pasiënte sowel as in 'n kontrole groep van 50 individue met dieselfde etniese
agtergrond. Die verband tussen die variasie by die lokusse en die kliniese kenmerke is
ondersoek. Geen statisties beduidende assosiasie is waargeneem vir hetsy die 4713
T>C SNP (P= 0.717) of die -64 C>T SNP (P= 0.931).
Genetiese modifiserende faktore word moeilik geïdentifiseer in klein populasies omdat
hulle afsonderlike bydra tot die geheelbeeld van die kliniese simptome so varieerbaar
is. 'n Relatiewe klein groep van VP pasiënte was tydens die studie beskikbaar en dus
kan assosiasie nie uitgesluit word nie. Die studie verskaf egter insig in verband met
toekomstige benaderings wat volg kan word in verdere ondersoeke van die ALAS en
PBGD gene. Verdere kennis in verband met die heem biosihtetiese padweg kan
uiteiHdelik lei tot die verduideliking en assesering van die kliHiese uitdrukking in vI='
individue.
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Chapter One
1 Introduction
1.1 Variegate porphyria
1.1.1 The disorder
Variegate porphyria (VP [MIM 176200]) is a low clinical penetrance autosomal
dominantly inherited disease. It is classified as one of the three acute hepatic
porphyrias, due to the fact that the overproduction and accumulation of the
porphyrins mainly occur in the liver (Dowdle et al., 1967; Meissner et al., 1986).
The clinical manifestations of the disease include acute neurovisceral attacks
and cutaneous photosensitivity that either occur separately or in combination
with each other. VP is found in most populations throughout the world, but has a
prevalence of 0.003 in the Afrikaans speaking population of South Africa (Dean,
1972). This high VP frequency is the result of a founder gene mutation effect.
The majority of VP patients in SA are therefore descendants of a couple who
came to the Cape of Good Hope and married in Cape Town in 1688 (Dean,
1972; Meissner et al., 1996; Warnich et al., 1996).
VP is characterized by a partial deficiency of protoporphyrinogen oxidase (PPOX
[E.C. 1.3.3.4]) encoded by the PPOX gene. In all the affected tissues studied to
date, which include fibroblast (Brenner and Bloomer, 1980), bone marrow
(Deybach et al., 1981a), leucocytes (McColl et al., 1985) and Epstein-Barr virus
transformed lymphocytes (Meissner et al., 1986), a 50% decrease in the PPOX
enzyme activity was found. This enzyme deficiency results in the increased
activity of 5-aminolevulinate synthase (ALAS [E.C. 2.3.1.3.7]) and the inhibition
of porphobilinogen deaminase (PBGD [E.C. 4.3.1.8]), which in turn result in the
overproduction and increased excretion of porphyrin and porphyrin precursors,
formed prior to the enzyme defect.
1.1.2 The biochemical profile of VP
The typical biochemical profile observed in most VP patients during the acute
and latent stages is an increase in the excretion of urine porphyrins, uro- and
coproporphyrins, and an increase in faecal copro- and protoporphyrins as well as
1
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pentacarboxylic porphyrins. An increase of uro-and protoporphyrins is also found
in the plasma. In the acute stage an increase in urinary excretion of porphyrin
precursors, 5-aminolevulinic acid (ALA) and porphobilinogen (PBG) may be
seen, but these values usually return to normal in the latent phase (Eales, 1963;
Herbert, 1966; Hamnstr6m et a/., 1967; Fromke et a/., 1978; Mustajoki, 1980).
VP is usually diagnosed by the measurement of faecal porphyrin concentrations;
however, variation in the biochemical profiles of patients makes diagnosis
problematic. Adult individuals with the gene mutation have shown normal
biochemical results. It is also difficult to distinguish between normal and "VP
levels" as food and bacterial metabolism in the intestine contribute to the
porphyrin content. A high excretion of porphyrins in the stool has also been
reported in patients with ulcerating lesions and carcinoma of the gastro-intestinal
tract, which could lead to false positives (Dean, 1972; Eales, 1979). To rule out
these environmental influences it was concluded that biliary porphyrin levels
provide a more accurate reflection of the intercellular porphyrin concentrations
than the faecal porphyrin level content. Normal faecal porphyrin excretion has
been demonstrated despite elevated biliary porphyrin and porphyrinogen (Logan
et a/., 1991; Kirsch et a/., 1998). The testing of biliary porphyrin levels is
however, not routinely performed since the bile can only be collected through
duodenal aspiration, which is an invasive procedure (Logan et a/., 1991).
A specific plasma porphyrin compound, unique to VP, shows a f1uorometric
emission at 626 nm when the excitation wavelength is set at 405 nm. This
biochemical procedure has proven a valuable tool in the diagnostic identification
of symptomatic VP adults, although the detection rate of asymptomatic adult
carriers and children is not precise (Poh-Fitzpatrick, 1980; Da Silva et a/., 1995).
1.1.3 The clinical symptoms associated with VP
Skin lesions and acute attacks that occur separately or in conjunction with each
other clinically characterize VP. Usually the disease does not present in
heterozygotes before puberty (Kauppinen and Mustajoki, 1992). The clinical
expression in VP patients varies considerably; even patients with the same
mutation from a single family were found to show different symptoms (own
unpublished results; Frank et a/., 2001a). Many individuals with a mutation
associated with VP, that expresses in other heterozygote individuals, remain
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clinically and biochemically latent. An individual can also show biochemical
abnormalities without expressing any associated clinical features (Kappas et al.,
1983). The full expression of VP may thus require genetic or environmental
factors in addition to a single mutation (Poh- Fitzpatrick, 1998).
Photocutaneous manifestations observed in VP individuals appear to be the
delayed result of sunlight exposure and the accumulation of hydrophilic oxidized
porphyrins. Skin symptoms are usually found in the areas, which are exposed to
sunlight such as the face, neck, hands and legs. These porphyrins, especially
protoporphyrin and coprotoporphyrin, absorb long ultraviolet and visible light
energy, which via an energy transfer process mediate the photochemical
reaction responsible for the skin damage (Mauk and Girotti, 1973). Clinical
features include photosensitivity, mechanical fragility, subepidermal blistering,
milia formation, postinflammation hyperpigmentation, hypertrichosis and scarring
(Poh- Fitzpatrick, 1998) (See Figures 1.1 and 1.2).
Symptoms of an acute attack can be explained by dysfunction of the nervous
system. Abdominal pain, which can reach severe levels, is observed in most
cases. Sympathetic outflow accounts for tachycardia, hypertension, sweating,
restlessness and tremor. The autonomic outflow includes vomiting, constipation
or diarrhea, hypertension, pathologic cardiovascular reflexes and bladder
dysfunction. Catecholamine hypersecretion may be responsible for renal
damage and has been implicated in sudden death caused by cardiac arrythmias.
Motor neuropathy that starts as distal muscle weakness in the arms or legs can
proceed to tetraplegia. The cranial nerves, especially the 7th and 10th, may
become affected leading to bulbar paralysis and respiratory failure.
Disorientation and psychosis may also feature during the acute attack (Poh-
Fitzpatrick, 1998; Thunell, 2000). Known precipitating factors of the acute attack
include drugs, for example barbiturates and thiopentone anesthetics, alcohol,
hormones, infection, fasting and stress (Moore, 1980). The mechanism for the
neuropathic manifestations has not been firmly established, but they all exhibit
the same biochemical profile, namely the excess accumulation of ALA and PBG
(Dean 1972; Mustajoki, 1978; Meyer and Schmid, 1978). The proposed
mechanisms of the acute attack include the induction of cytochromes, including
cytochrome P450, through many drugs. This results in the increased utilization
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of haem and the further depletion of the haem pool. As a result of a decrease in
the negative feedback control, ALAS activity is then derepressed (Meissner et
al., 1987). Agents such as sulphonamides may also have a direct effect on the
haem pathway by inhibiting the enzyme that controls it (Peters et aI., 1980).
Alcohol probably acts via both the above-mentioned routes, while the
mechanisms utilized with hormones, fasting, stress and infection are still unclear
(McColl and Moore, 1981; Thadani et aI., 2000).
The homozygous inheritance of VP was first reported by Kordac et al. (1984).
Symptoms in these individuals are already observed in early infancy and it was
established that they indeed had a very low activity of the PPOX enzyme (9-25%)
(Kordac et aI., 1984; Mustajoki, 1980; Murphy et aI., 1986; Mustajoki et aI., 1987;
Norris et aI., 1990). The clinical symptoms include severe photosensitivity
accompanied by mental and/or growth retardation, brachydactyly, nystagmus and
convulsions (Hift et aI., 1993; Roberts et aI., 1998). About twelve cases have
been reported to date in which most result from heteroallelic mutations (Meissner
et al., 1996, Frank et aI., 1998; Roberts et aI., 1998; Corrigall et al., 2000;
Kauppinen et aI., 2001; Palmer et aI., 2001) and two cases were found to be due
to homoallelic mutations (Roberts et al., 1998).
1.1.4 The treatment of VP
Individuals with VP should be made aware of the importance of avoiding agents
and circumstances that might trigger an acute attack or aggravate chronic
symptoms. Anaesthesia has also been implicated in the triggering of a number
of severe porphyric reactions. The total dose of the drug(s) and the length of
exposure time may influence the likelihood of an acute attack. Safe anesthetic
management includes the identification and avoidance of potentially
porphyrinogenic agents (James and Hift, 2000).
Avoiding sunlight exposure and taking great precautionary measures to protect
the skin is very important for VP patients (Thadani et al., 2000). No treatment is
currently available to improve the skin conditions associated with VP.
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Figure 1.1: The hands of a 54-year-old female VP patient showing signs of
discolouration
Figure 1.2: The hands of a 59-year-old male VP patient showing severe signs
of skin damage
5
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Therapies associated with the acute attack include the administration of safe
drugs to alleviate the clinical symptoms present during the attack, the intake of
carbohydrate, and haem therapy. Pain can be treated with paracetamol
although it is usually not sufficient. In severe cases pethidine or morphine
should be used. Nausea and vomiting can be treated with promazine or
chlorpromazine. Great care should be taken to ensure adequate fluid and
electrolyte (sodium, potassium, magnesium, calcium) intake. The acid-base
balance should also be corrected and maintained. Hyponatraemia can be
managed with fluid restriction, and hypertension and tachycardia can be treated
with P-blockers (Meissner et ai., 1987; Thadani et ai., 2000).
High oral or intravenous carbohydrate intake throughout the acute attack is very
important as it reduces porphyrin synthesis. The mechanism is explained by the
effect of haem depletion on gluconeogenesis (Correia and Lunetta, 1989). There
is an observed decline in ALA and PBG excretion during glucose therapy, which
can be explained by a glucose-mediated repression of ALAS (Moore, 1998).
Haem administration during the early stages of an attack has proven very
beneficial to controlling the acute attack and reducing the clinical neurological
complications (Tenhunen and Mustajoki, 1998). Haem is intravenously
administered as haematin (pH 8.0), the hydroxide of haem, since this is the only
aqueous soluble state of haem (Bissell, 1979). The haematin goes to work by
restoring the depleted intracellular 'free haem pool' and therefore reducing the
activity of ALAS and the overproduction of porphyrin and porphyrin precursors.
The normal cellular function is thus restored (Watson et ai., 1973; McColl and
Moore, 1981). The co-administration of haematin and tin protoporphyrin, an
inhibitor of haem oxygenase, have shown to be very efficient in prolonging the
working state of the haematin therapy (Kappas et ai., 1984; Drummond, 1989;
Dover et ai., 1991; Dover et ai., 1993). Unfortunately tin protoporphyrin has
significant side effects viz. cutaneous photosensitivity and toxicity, which should
be further investigated before it can be routinely used (Mark and Maines, 1992;
Moore, 1998).
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1.1.5 The PPOX gene
The PPOX gene was mapped to 1q22-23 (Taketani et al., 1995) and it was
shown that the disorder VP is linked to DNA markers in this region (Roberts et
al., 1995). The 5kb gene was shown to be present in single copy by Southern
blot analysis and the same transcripts were found in both erythroid and
nonerythroid cells (Taketani et al., 1995; Puy et al., 1996). The gene consists of
twelve coding exons and one non-coding exon and the human PPOX cDNA
(1.7kb) encodes a 477 amino acid protein (Nishimura et a/., 1995).
The promoter of the PPOX gene is a typical housekeeping promoter with a GC
content of 59% and several cis-acting regulatory elements. An SP1 site is found
at nt-829 to nt-834, a GATA-1 site is described at nt-738 to nt-743 and a CCAAT
box is found at nt-505 to nt-509. There is no TATA box present in the promoter
(Taketani et al., 1995).
Mutation analysis shows extensive allelic heterogeneity, where some 100
mutations are reported worldwide, except in the South African population where
the R59W mutation dominates due to the founder effect (Frank et al., 1999,
2001a, 2001b; Whatley et al., 1999a; Corrigall et al., 2000, 2001; De Siervi et al.,
2000a, 2000b; Maeda et al., 2000; Kauppinen et al., 2001; Lam et al., 2001;
Palmer et al., 2001; Von und zu Fraunberg et al., 2001; Donnelly et al., 2002;
Human gene mutation database hUp:/Iwww.hgmd.org [Krawczak and Cooper,
1997]). Evidence for the existence of a founder mutation was also found in Chile
(1239deITACAC) and Finland (R152C) (Von und zu Fraunberg and Kauppinen,
2000; Frank et al., 2001a). To date ten different mutations have been detected
in South Africa. These include the founder gene mutation R59W and the H20P,
537de1AT, c769deiG 770T>A, L15F and Q375Y mutations (Meissner et al.,
1996; Warnich et al., 1996; Corrigall et al., 1998; Corrigall et al., 2001). The
V290M variant was the only mutation found in a Black South African of
indigenous origin (Corrigall et al., 2001). The R168C, R138P and the Y348C
mutations were found in compound heterozygotes, heteroallellic to the common
R59W mutation (Meissner et al., 1996; Warnich et al., 1996; Corrigall et al.,
2000).
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In previous studies it was demonstrated that the type of mutation did not
influence the clinical presentation, and the distribution of clinical symptoms in
studies in the United Kingdom (U.K.) and Western Europe were found to be
identical to the results found in South Africa (Eales et a/., 1980; Kirsch et a/.,
1998; Whatley et al., 1999a). It is thus concluded that the genotype of the PPOX
gene is not a significant determinant of the mode of presentation and that
environmental influences and the genetic effects from other loci are likely to be
more important in the phenotype-genotype relationship (Elder, 1998;
Grandchamp, 1998; Poh-Fitzpatrick, 1998; Whatley et al., 1999a).
To date some 17 single nucleotide polymorph isms (SNPs) have been described
in the PPOX gene (See Table 1.1). One SNP is described in the promoter
region (Warnich et a/., 2001), eight SNPs are found in the exonic areas of the
gene (Deybach et a/., 1996; Warnich et a/., 1996, 2001; Kotze et al., 1998;
Whatley et a/., 1999a), seven SNPs are found in the intronic areas (Puy et a/.,
1996; Lam et a/., 1997; Whatley et a/., 1999a; Biochip:
http://www.bio.chip.org/biotools/) and one SNP is found in the 3'untranslated
area of the PPOX gene (Biochip: http://www:bio.chip.org/biotoolsl).
Table 1.1: The SNPs identified in the PPOX gene
Position Previous Area in Method of Reference
numbering gene detection
-1081 A>G Promoter SSCP; Hae 11/ Warnich et al.,
2001
-420 G>C -253 (1-22) Exon 1 HEX-SSCP Kotze et a/.,
1998
-414 A>C -247 (1-26) Exon 1 SSCP; Direct Warnich et a/.,
sequencing 1996
-413 G>T -246 (1-27) Exon 1 HEX-SSCP Kotze et a/.,
1998
-318 G>T -151 (1-127) Exon 1 HEX-SSCP Kotze et a/.,
1998
-295 C>G -118 (1-150) Exon 1 Direct sequencing; Warnich et a/.,
Ban" 1996
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+206 G>C IVS2-47 Intron 2 HDA; Msp I Lam et aI.,
1997
+820 G>A IVS4-327 Intron 4 Hint I Puy et aI.,
821G>A 1996
+1498 C>T Intron 5 Direct Sequencing Biochip
+1908 A>C IVS6-237 Intron 6 Direct sequencing Puy et aI.,
1909 A>C 1996
+1995 T>C IVS6-150 Intron 6 Ste I Puy et aI.,
1996 T>C 1996
+2296 C>G 767 (P256R) Exon 7 HDA Whatley et al.,
1999a
+2929 A>C IVS8+57 Intron 8 DGGE Whatley et al.,
1999a
+3100 G>A 911 (R304H) Exon 9 DGGE; BssSI Deybach et al.,
1188 G>A 1996
+3750 G>C IVS10-22 Intron 10 DGGE Whatley et aI.,
1999a
+3880 A>C G402 Exon 11 SSCP Warnich et aI.,
2001
+4752 C>T 3' UTR Direct sequencing Biochip
1.2 The other Porphyrias
The porphyrias can be divided into three main groups based on their clinical
expression. The position of the enzyme deficiency in the haem cycle determines
the resulting haem precursor accumulation patterns and thus the clinical and
biochemical phenotypic expression. The acute porphyrias consist of ALA
dehydratase deficiency porphyria (ALADP) and acute intermittent porphyria (AlP)
(See Figure 1.3). Both of these disorders are associated with neurological
manifestations, due to a surplus of 5- aminolevulinic acid or the deficit of vital
haemproteins resulting from reduced haem synthesis. The cutaneous porphyrias
include congenital erythropoietic porphyria (GOnters disease), porphyria cutanea
tarda (PCT) and erythropoietic protoporphyria (EPP) (See Figure 1.3). The
cutaneous porphyrias are due to the impairment of the porphyrin processing
steps, which in turn give rise to the accumulation of phototoxic porphyrins in the
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skin. The last clinical classification groups consist of hereditary coproporphyria
and variegate porphyria. These two types of porphyrias express both cutaneous
and neurological manifestations (See Figure 1.3). Chester porphyria is clinically
classified as a combination of acute intermittent porphyria and variegate
porphyria, and therefore exhibits neurological and cutaneous manifestations. Both
these clinical symptoms are also found in dual porphyria, which is represented by
a combination of variegate porphyria and porphyria cutanea tarda.
Figure 1.3: A summary of the clinical classification groups of the different
porphyrias
The porphyrias
Acute
Attacks -----i .... 1. ALADP
2. AlP
Cutaneous -------.
manifestations
3. CEP
4. PCT
5. EPP
Both
6. HCP
7. VP
-----i.... 8. Chester porphyria
9. Dual porphyria
ALA dehydratase deficiency (ALADP [MIM 125279]), also sometimes referred to
as plumboporphyria has only been described in a very few cases. This disease is
due to mutations in the ALA dehydratase (ALAD [E. C.4.2.1.24]) gene and only
manifests in the homozygous state when a precipitating factor is present (Mercelis
et al., 1990). Precipitating factors include estrogen and progesterone, alcohol,
drugs that induce the cytochrome P450 system, decreased caloric intake and
acute physical and psychological stressors. The initial presentation has ranged
from infancy to an individual 63 years of age. The clinical symptoms of this
disease mimic those associated with acute intermittent porphyria. Laboratory
investigation revealed that these patients have normal PBG excretion, but
increased ALA levels in their urine. The complete blood count was also found to
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be in the normal range, although there is a marked decrease in the red cell ALA
dehydratase activity (Shumate, 2002). Treatment of ALA dehydratase deficiency
includes the identification and avoidance of precipitating factors. Intravenous
hematin treatment can be administered to relieve the symptoms associated with
an acute attack.
Acute intermittent porphyria (AlP [MIM 176000]) (see 1.4.2.2 for detailed
discussion) is an autosomal dominant disease due to mutations in the PBGD
gene. AlP is found in 1 to 2 individuals per 100,000. This disease presents after
puberty and the clinical symptoms include acute neurological attacks. An
accumulation of porphobilinogen is found in the urine of AlP patients (Kappas et
al., 1995).
Erythropoietic protoporphyria (EPP [MIM 177000]) occurs in 0.1 per 10 000
individuals. It is an autosomal dominant disease due to mutations in the
ferrochelatase (FC [E.C. 4.99.1.1]) gene, but very rarely also seen to inherited in
an autosomal recessive manner (Sassa et aI., 1982; Sarkany and Cox, 1995).
Light sensitive dermatitis, which is already present in early childhood, is the
primary clinical symptom associated with this disease (Peterka et al., 1965; De
Leo et al., 1976). Burning and itching of the skin after sun exposure is
accompanied by erythema and oedema. The chronic lesions result in the scarring
and thickening of the skin. Severe liver disease was found to be present in 10%
of EPP patients and protoporphyrin rich gallstones can also be present.
Laboratory findings in EPP patients include the deficiency of ferrochelatase,
causing protoporphyrin to accumulate in excessive levels in erythrocytes, bile and
faeces. Mild microcytic hypochromic anemia is present in 20% to 30% of EPP
cases (Rademakers et ai., 1993). Beta-carotene can be taken by these patients
to increase the tolerance of sunlight exposure. Red blood cell transfusion and the
administration of hematin were found to be effective treatment in the reverse of
hepatic protoporphyrin accumulation.
Congenital erythropoietic porphyria or GOnters disease (CEP [MIM 263700]) is an
exceedingly rare autosomal dominant disorder characterized by mutations in the
uroporphyrinogen III synthase (UPGIllS [E.C. 4.2.1.75]) gene (Levin 1968; Romeo
and Levin 1969; Romeo et ai., 1970). This disease already presents in early
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mutations in the HFE gene represent susceptibility factors for PCT but do not
explain all iron metabolism disorders observed in sPCT (Lamoril et ai., 2002). It
should be taken in to account that sPCT is multifactorial in the individual patient
and is seldom attributal to a single identifiable cause (Egger et ai., 2002). Familial
PCT is an autosomal dominant disorder due to mutations in the URaD gene
(Romana et ai., 1987). Hepatoerythropoietic porphyria is a severe form of PCT
and already present in infancy. These patients were found to be homozygous for
mutations in the URaD gene (De Verneuil et ai., 1984). The skin symptoms
associated with PCT were shown to improve after treatment with phlebotomy (as
this reduces excess iron associated with the disease) and antimalarial drugs (the
chloroquine forms a complex with uroporphyrin and promotes the release of
uroporphyrin from the liver (Kordac et ai., 1989)).
Hereditary coproporphyria (HCP [MIM 121300]) is an autosomal dominant
disorder characterized by defects in the coproporphyrinogen oxidase (CPGO [E.C.
1.3.3.3]) gene (Martasek, 1998). HCP is rare in all parts of the world and 20 times
less common than AlP. The clinical manifestations associated with HCP include
both skin and neurological symptoms. Open sores and blisters form especially
after exposure to the sun. The neurovisceral symptoms were found to be present
in a higher percentage of the patients compared to cutaneous symptoms (Poh-
Fitzpatrick, 1998). Elevated porphyrin content is found in the blood, urine and
stool. Diagnosis is usually proven by the high coproporphyrin content in the stool.
During an acute attack there is usually an increase of ALA and PBG in the urine
(Barnes and Whittaker, 1965; Goldberg et al., 1967).
Chester porphyria [MIM 176010] is very rare and only described in the city of
Chester, England. The clinical features include those associated with AlP and
cutaneous photosensitivity is not a feature of Chester porphyria (McColl et al.,
1985). The activity of both PBGD and PPOX is reduced in these patients, but this
dual enzyme deficiency is found to be associated with a locus on chromosome 11,
which is separate from the PBGD locus (Norton et al., 1993). The pattern of PBGD
activity in Chester porphyria is lower than the value found in VP patients, but
identical to the activity in patients with AlP (Moore, 1998). The excretion patterns
of the porphyrins form an intermediate between AlP and VP.
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childhood and is associated with light sensitive skin. Cutaneous lesions such as
vesicles or bullae formation form on the light exposed skin. After repeated
ulceration and erosion scaring occurs which can cause severe deformities. Other
symptoms include hypertrichosis, alopecia, conjunctivitis, keratitis and alterations
in pigment. Red urine is also observed and in a few cases the teeth are stained
red (Dean 1972; Meyer and Schmid, 1978; Deybach 1981b). Porphyrins are
deposited in bone, where they cause orange-red fluorescence. The severe loss of
bone that results in deformities occurs in most adults with CEP. CEP is
associated with the lifelong overproduction of series I porphyrins, which include
uroporphyrin I and coproporphyrin I. These porphyrins are circulated and
deposited in the plasma, red blood cells, urine and faeces.
Porphyria cutanea tarda (PCT [MIM 176090]) is the most frequently found type of
porphyria, but to date no figure for prevalence exist. This disease is clinically
defined by light sensitive dermatitis and bullous dermatosis that forms scars and
milia during the healing process. Hypertrichosis and areas of increased
pigmentation are also observed (Elder et al., 1978; Elder, 1998). The clinical
symptoms normally present in later adult life. Large amounts of uroporphyrin are
excreted in the urine and the overloading of iron is frequently observed (Elder et
aI., 1978; Felsher et aI., 1982). PCT can be divided into three subgroups; include
sporadic (sPCT), familial and hepatoerythropoietic porphyria. Sporadic PCT
accounts for 80-90% of all PCT cases and is not due to mutations in the
uroporphyrinogen decarboxylase (URaD [E.C. 4.1.1.37]) gene, but the result of
the generation of an inhibitor of the URaD enzyme activity, that is restricted to the
liver (Garey et aI., 1993). Alcohol is the most important agent responsible for the
acquired disease, but estrogen steroids, iron overload, viral hepatitis and
fungicides such as hexachlorobenzene have been found to be causative agents.
Hereditary hemochromatosis (HH) is an inherited disease of excess iron storage
in target organs such as the liver and has been implicated in the development of
sPCT in some populations (Hift et aI., 1997; Roberts et aI., 1997; Sherlock and
Dooley, 1997; Bonkovsky et al., 1998; Elder and Worwood, 1998; Bulaj et al.,
2000). HH is caused by mutations in the hemachromatisis (HFE) gene (Feder et
al., 1996). Analysis of HFE gene indicated that the C282Y, but not the H63D or
the S65C genotypes, is a susceptibility factor for the development of sPCT in
West European continental patients (Lamoril et aI., 2002). Results suggest that
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Dual porphyria is found in 25% of all VP patients. The clinical features include
those of VP, although they can be present in a more severe form (Day et al.,
1982). The activity of both uroporphyrinogen decarboxylase and
protoporphyrinogen oxidase is reduced (Sturrock et al., 1989). The urinary and
faecal porphyrin profiles represent the superimposition of those found in PCT and
VP. Diagnosis is based on the concentrations of faecal protoporphyrin, 7-carboxyl
porphyrin, coproporphyrin and isoproporphyrin and the increased concentration of
uroporphyrin and 7-carboxyl porphyrin found in the urine.
1.3 The haem pathway
In evolutionary terms, the haem biosynthetic pathway is highly conserved. An
eight-step process by which the pigment haem is formed and metabolized is found
in almost all species from bacteria to humans (Mauzerall, 1998; Thunell, 2000).
The only difference is found in the starting material used. Most of the biosphere,
for instance all plants, uses glutamate for the formation of ALA. Mammals use
glycine succinate, which on entry into the cycle undergoes a condensation-
decarboxylation reaction to form ALA. The haem biosynthesis cycle has two
places where it can divaricate. The synthesis of cobalamine, managed by some
organisms, is done by the methylation and rearrangement of the carboxylic
porphyrinogen formed in the fifth step of the haem biosynthetic pathway (See
Figure 1.4). In plants chlorophyll is generated by the incorporation of magnesium,
while iron is incorporated to produce haem (Thunell, 2000).
All the mitochondrial containing cells of the body have the capacity to produce
haem. Most of the haem synthesis takes place in the bone marrow and muscle
tissue. Although less haem is produced in the liver (15% of the total daily
production), this takes place at a more rapid and flexible rate. The haem formed in
the liver is used as a prosthetic group in enzymes, where more than half are used
for the formation of microsomal P450 cytochromes. Haem synthesized in the bone
marrow and muscle tissue is used to form red blood cell hemoglobin and muscle
tissue myoglobin. The control mechanism for the rate of production differs from
hepatic synthesis with the red cell precursors being designed for uninterrupted
steady production of great amounts of haem. The synthesis of the enzymes that
take part in the haem pathway, in the erythron, is under control of erythropoietin.
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Erythropoietin is formed under hypoxic conditions. (The haem biosynthetic
pathway is illustrated in Figure 1.4.)
The haem biosynthetic pathway engages four mitochondrial steps, viz. steps 1, 6,
7,8 and four cytoplasmic reactions steps viz. 2, 3,4,5.
The synthesis starts with the two hydrophilic amino acids, glycine and succinate,
that condense to form 5- aminolevulinic acid (ALA). The demerization of ALA to
porphobilinogen (PSG) that is under the control of the enzyme 5-aminolevulinate
dehydratase (ALAD) forms the second step of the cycle. In the third step PSGD
catalyzes the stepwise deamination and the condensation of four molecules of
porphobilinogen, resulting in the formation of the unstable linear tetrapyrrole pre-
uroporphyrinogen. In step four, on enzymatic rearrangement of the side chains,
the molecule ring closes. The first porphyrin structure, the highly water-soluble III-
isomeric uroporhyrinogen, is thus generated. In parallel, the metabolic inert 1-
isomeric form of uroporphyrinogen is formed spontaneously and excreted with
coproporphyrin-I, the partially decarboxylated product of uroporphyrinogen. In
step five, by a sequence of decarboxylations, four acetate groups are removed
from the side chains of uroporphyrinogen-III, leaving a less water- soluble
molecule coproporphyrinogen-III with four propionate groups.
Coproporphyrinogen oxidase, the enzyme that catalyzes the sixth step in the
pathway, converts the two propionate groups at positions 2 and 4 of
coproporphyrinogen-III to two vinyl groups, thus producing sequentially,
harderoporphyrinogen-IX and protoporhyrinogen-IX. PPOX catalyzes the six-
electron oxidation of protoporphyrinogen-IX to protoporphyrin -IV that forms the
seventh step of the cycle. The final step takes place when ferrochelatase
catalyzes the insertion of ferrous iron into the protoporphyrin-IV to form haem.
The initial three enzymes of the pathway, ALAS, ALAD and PSGD, are
synthesized in duplicate forms. The one form is ubiquitously expressed in all
tissue, while the second form is only expressed in erythroid cells. Tissue
specificity is determined by control elements in the promoter regions of these
genes. The promoter region of the ubiquitous form contains the transcription
factor Sp1, while the erythroid specific form's expression is determined by the
activation of the GATA-1, CACCC box and NF-E2 binding sites (May et aI., 1995).
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The two ALA isoenzymes are encoded by different genes and have different
mechanisms of regulation (Bawden et ai., 1987; Cox et ai., 1991). The ALAD and
PBGD isoenzymes arise from only one gene, which contains separate
housekeeping and erythroid promoters. The different mRNAs are thus formed
through tissue specific alternative splicing (Chretien et al., 1988; Mignotte et ai.,
1989; Kaya et ai., 1994).
There is no evidence for the existence of isoenzymes in the case of the other four
enzymes UPGIIIS, CPGO, PPOX and FC. These enzymes are all coded by a
single gene, which is identically expressed in erythroid and other tissue (May et
ai., 1995). The promoter in the UROD gene contains a ubiquitous Sp1 binding
site, but to date no erythroid control elements have been identified (Thunell,
2000).
Of all the enzymes, the lowest activity is found for ALAS, the first enzyme in the
pathway. ALAS is rate-limiting for the entire synthetic process and its activity is
determined by the availability of the amount of free haem that is present within the
cell.
The enzyme haem oxygenase-1 (Hemox [E.C. 1.14.99.3]) controls the amount of
free haem. Hemox is ubiquitously expressed, but present in higher concentrations
in the liver and spleen, the main areas of hemoglobin degradation. After splitting
of the porphyrin ring to liberate the iron, the haem molecule is degraded to
biliverdin (Step 9, Fig.1.4). In one further step, bilirubin is formed and excreted via
the liver-bile route. The liberated iron is then re-utilized in the body (Thunell,
2000).
The pathway normally operates at high efficiency: intermediates are utilized nearly
quantitatively, so that less than 1% escapes from the biosynthetic route to appear
in blood and undergo excretion.
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Figure 1.4: An illustration of the haem biosynthetic pathway
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1.4 Mod ifier genes
1.4.1 The role of modifier genes
The classification of genetic disorders into chromosomal, monogenetic and multi-
factorial became insufficient and problematic (Romeo and McKusick, 1994;
Scriver and Waters, 1999; Dipple and McCabe, 2000). It became apparent that
a consistent correlation between the mutant genotype and the variant phenotype
was not possible and certain single gene traits began to be considered as a
version of complex traits. The presence of a particular genotype increases the
risk of developing a certain phenotype, but is not vital for its expression, nor
sufficient to explain the development of the disease (Nadeau, 2001). Three
causes of variable phenotypic expression include the presence of alternative
alleles, the physiological interactions of environmental factors, and modifier
genes (Nadeau, 2001; Van Straaten and Copp, 2001). Multiple genes, each only
contributing to a small proportion of the phenotypic difference, seem to operate
through modifying susceptibility.
Modifier genes can be traced back to studies done by Bateson et al. in 1905 (as
cited by Rao, 2001) on the inheritance of colour in flowers. Two versions of
modifier genes exist:,one that modifies positively (disease promoting) and one
that modifies negatively (disease suppressing) (Nadeau, 2001). Modifier genes
influence penetrance, the frequency of expression of an allele, expressivity, and
pleiotropy. The understanding of modifying genes and disease loci will solve
problems associated with variable disease presentation and lead to disease
therapeutics. Modifier factors of genetic origin can be classified into three
categories viz. allelic variation involving the disease gene itself, a locus
genetically linked to the a disease gene, and disease gene independent locus
(Feingold, 2000 as cited by Nadeau, 2001). Examples, discussing each of these
categories, will follow.
A) Allelic variation involving the disease gene itself:
Investigations on cystic fibrosis (CF [MIM 219700]), a recessive disease, pointed
to a modifying influence of factors other than the respective mutations in the
cystic fibrosis transmembrane conductance regulator (CFTR) protein, when
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clinical variation was observed among unrelated individuals with the same CFTR
genotype. Congenital bilateral absence of the vas deference (CBAVD [MIM
219700]) is a form of obstructive azoospermia and the cause of infertility in 1-2%
of males (Jequier et al., 1985). CBAVD patients have a distinct but overlapping
spectrum of mutations in the CFTR gene, comparable with those observed in CF
patients. Three known alleles with a variable number of thymidines (5,7,9) in a
polythymidyl tract (T-tract) of the acceptor splice site were found in intron 8 of the
CFTR gene (Chu et al., 1993). A variable level of aberrant CFTR mRNA,
missing exon 9, which was shown to have defective chloride channel function, is
consequently produced (Strong et al., 1993). The amount of incomplete
transcripts was found in reverse proportion to the length of the T-tract alleles.
The variant with the 5 thymidines (ST) is therefore typically associated with the
highest proportion of the aberrant CFTR variant and the lowest amount of the
normal variant (Chu et aI., 1993). The ST allele rarely causes CF, but can modify
a phenotypic effect of other mutations. The R117H missense mutation is present
in both CF and CBAVD patients. The R117H allele associated with the ST
variant is found in CF patients whereas it is associated with the 7T variant in
CBAVD patients. The R117H mutations on the 7T background affect almost
exclusively the male reproductive tract and are not sufficient to produce CF
symptoms, whereas the ST alleles enhances the phenotypic effect of the R117H
mutation producing the pancreatic sufficient form of CF. In conclusion, the
variation found in intron 8 of the CFTR gene influences the effect of the R117H
mutation on the phenotype.
A second example of this interaction is illustrated by a mutation in the prion gene
(PRPN) on chromosome 20. This mutation results in an Asp178Asn (G>A)
substitution. The mutation was found to be the cause of two different autosomal
dominant inherited prion disorders. The diseases Creutzfeldt-Jakob disease
(CJD [MIM 123400]) and familial fatal insomnia (FFI [MIM 176640]) both
represent spongiform degeneration of the brain. A widespread degenerative
cerebral process characterizes CJD, while FFI is characterized by a severe
atrophy of the thalamic nuclei. A common MeWal (A>G) (with the ratio of 62%
to 38%) polymorphism in codon 129 of the PRPN gene generates two alleles.
The Met 129 and Asn 178 combination results in the disease primarily localized
to the thalamus. This phenotype is associated with FFI. The Val 129 and
19
Stellenbosch University http://scholar.sun.ac.za
Asn 178 combination has a more widespread disease process associated with
the CJD phenotype (Goldfarb et al., 1992).
A third example includes erythropoietic protoporphyria (EPP) where it was found
that an intronic SNP modifiES the degree of penetrance (Gouya et al., 2002)
(See section 1.2 for clinical features of disease). EPP is caused by a partial
deficiency of ferrochelatase. The disease is transmitted in an autosomal
dominant manner with incomplete penetrance (Sassa et al., 1982). Gouya et al.
(2002) identified an intronic SNP (IVS3-48T>C) that modulates the use of an
atypical acceptor splice site. The aberrantly spliced mRNA is degraded by a
nonsense-mediated decay mechanism (NMD), producing a decreased level of
mRNA (Gouya et al., 2002). By genotyping 25 EPP family members they
observed that all the individuals with overt EPP had in trans to a specific Fe
mutated allele, the IVS3-48C SNP which cosegregates with the low-expression
Fe allele. The IVS3-48T allele cosegregates with the normal expression allele in
all the asymptomatic carriers. Gouya et al. , (2002) thus showed that the
phenotypic status associated with the disease depends on the co-inheritance of
a severe Fe defect and a common low-expression variant IV3-48C allele.
B) A Locus genetically linked to the disease gene:
Spinal muscular atrophy (SMA [MIM 253300]), a common recessive disorder, is
characterized by the loss of motor neurons in the spinal cord. All patients display
deletions or gene conversions of the survival motor neuron (SMNI) gene
(Lefebvre et al., 1995; Rodrigues et a/., 1995; Hahnen et a/., 1996; Van der
Steege et al., 1996). SMA is classified into three types (SMA I, SMAil, SMAil!)
based on the age of onset and the severity of the disease. SMA I is the most
severe phenotype of the disease followed by SMA II and lastly SMA III. All three
classifications of SMA mapped to chromosomal region 5q13 (Brzustowicz et al.,
1990; Melki et a/., 1990). The majority of SMA I patients display a large-scale
5q13 deletion removing the SMN1 gene and adjacent microsatellite markers
C272 and C212 (DiDonato et a/., 1994; Burlet et al., 1996). Additional modifying
factors were believed to exist that contribute to the severity of type I SMA.
Scharf et al. (1998) identified a novel transcript, H4F5, which is located closer to
the SMN1 gene than any previously identified genes in the region. A multi-copy
microsatellite marker, C212, that is deleted in more than 90% of type I SMA
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chromosomes was found to be imbedded in an intron of this H4F5 gene. The
deletion frequency of the C212 marker in type II SMA was found to be between
that of type I and the control chromosomes, whereas deletions in type III SMA
chromosomes were only slightly more frequent than in the controls. The deletion
frequency of the C212 marker in the H4F5 gene in the three groups of the SMA
populations thus correlates with the disease severity. It is therefore concluded
that H4F5 is a candidate phenotypic modifier for SMA (Scharf et a/., 1998). The
exact function of the H4F5 gene is still unknown, but futher studies of the H4F5
protein will reveal if it functions in the small nuclear ribonucleoprotein (snRNPs)
biogenesis like the SMN protein. It was found that the H4F5 protein shows
homology to an snRNP interacting protein that co-localizes with the same
proteins as SMN (Scharf et al., 1998).
C) Disease gene independent modifying locus:
The Cyclin 01 (GGN01) gene was found to be a genetic modifier in hereditary
non polyposis co Iorecta I cancer (HNPCC [MIM 114500]) (Bala and Peltomaki.
2001). HNPCC is associated with an inherited predisposition to colorectal
carcinoma and a variety of extracolonic cancers. HNPCC is linked with germ-
line mutations in one of the five (MLH 1, MSH 2, MSH 6, PMS 1, PMS 2)
mismatch repair (MMR) genes (Lynch and Smyrk, 1996). To date there are
more than 300 identified mutations (Peltomaki and Vasen, 1997). Significant
phenotypic variation has been reported in HNPCC patients, which could not be
explained by the different predisposing mutations. It was thus concluded that
other factors beside the mutations in the MMR genes influence the phenotypic
expression. The GGN01 gene is a good candidate for a modifier gene locus in
cancers. GGNO1 encodes a protein that plays an important role in the cell cycle
control in normal cells and neoplasia (Donnellan and Chetty, 1998). It also
exhibits alternative mRNA splicing. A G>A polymorphism at the splice donor site
of exon 4 was considered to increase alternative splicing (Betticher et al., 1995).
In the latter study the different alleles of the G>A polymorphism in codon 242 of
the GGN01 gene was identified through SSCP analysis in patients who had a
predisposing mutation in either the MLH1 or MSH 2 gene. No correlation was
found between the different genotypes and the colonic location of the cancer or
the occurrence of extracolonic cancers. No correlation was observed between a
particular allele (A versus G) and the age of onset of cancer, but the average age
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of onset was higher in heterozygous individuals (AG, 46 years) as compared with
homozygous individuals with the normal allele (GG, 41 years) or the variant
allele (AA, 39 years) (Bala and Peltornáki, 2001). Therefore the results suggest
that the co-existence of A and G transcripts in the GGN01 gene, modify the age
of onset of colon cancer in hereditary nonpolyposis colorectal cancer.
The modifying effect of the endothelial NO synthase (ENOS) gene in autosomal
dominant polycystic kidney disease (ADPKD [MIM 601313]) was shown by Persu
et al. (2002). ADPKD, an autosomal dominant disease, is one of the most
common monogenic hereditary diseases. ADPKD is characterized by the
development of multiple cysts in both kidneys. The cysts continue to grow until
renal failure occurs. ADPKD is due to mutations in two major genes, PKD1
found at chromosome location 16p13.3 and PK02 found at chromosome location
4q21-q23 (pirson et al., 1998). PK01 mutations are responsible for 85% of all
cases and PK02 mutations for the vast majority of the remaining cases. PK02
mutations were found to express a clinically milder phenotype than PKD1
mutations (Hateboer et al., 1999). A substantial variability is observed in the
severity of renal phenotype, primarily assessed by the age at end-stage renal
disease (ESRD). The release of nitric oxide (NO) by endothelial cells plays a
critical role in the control of local haemodynamics and systemic blood pressure
(Vallance et al., 1989; Forte et al., 1997). APDKD is associated with an
alteration of the endothelium-dependent vasodilation, that has been attributed to
a decreased production of NO by endothelial NO synthase (eNOS [E.C.
1.14.13.39]) (Wang et al., 2000). It was thus speculated that small changes in
the NO levels may playa role in the progression of renal disease and ENOS, the
gene coding eNOS, found at chromosome location 7q35-36, could be a modifier
gene in ADPKD (Marsden et al., 1993). In the study by Persu et al. (2002) the
influence of the three most studied polymorphisms (Glu298Asp; intron 4 VNTR;
T-786C) of the ENOS gene was assessed on the age at ESRD in males and
females from a large series of unrelated ADPKD patients. No effect on the age
at ESRD was found for the intron 4 and T-786C polymorphisms. The Glu298Asp
polymorphism was associated with a significantly lower age at ESRD in the
ADPKD males and was over-represented in the subset of ADPKD males
reaching ESRD before the age of 50 years. The production of NO through
eNOS is regulated by estrogens (Goetz et al., 1994; Chambliss et al., 2000)
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which might explain a gender sensitivity to NO (Majmudar et al., 2000) and the
observation that the effect of the Glu298Asp polymorphism was restricted to
ADPKD males. Expression studies revealed that the ENOS activity was
systematically lower in patients with the Glu/Asp or Asp/Asp genotype. These
results thus show that the ENOS gene can possibly modify the clinical
expression found in ADPKD, although further studies in other populations with
different genetic backgrounds should be done to support the results. This is
particularly true if the Glu298Asp polymorphism is not the causal polymorphism,
but only a marker in linkage disequilibrium with the modifier locus (Persu et al.,
2002).
1.4.2 Candidate modifier genes considered in this study
Great variation in the clinical expression of VP is found in the South African
founder population. Since the majority of VP patients share an identical disease
causing mutation, it was concluded that environmental factors or modifier genes
contribute to the variation found in the phenotypic expression (Warnich et al.,
2002). Variation between sibs could not be explained by environmental factors
alone as we expect sibs to be exposed to the same environmental factors. The
starting point when searching for modifier genes would include sequence
variation found in the PPOX gene itself. As the PPOX gene is already under
investigation as part of a current research project (Warnich et al., 2002; Warnich
unpublished results), it was decided that a search for modifier genes should
include other genes of the haem pathway that play an important role in regulating
the pathway. The rate of the haem synthesis is regulated by a negative
feedback control mechanism, through the activity of the initial enzyme, ALA
synthase. Secondary control lies at the level of the third enzyme, PBG
deaminase, which has a low endogenous activity and is inhibited by proto- and
coproporphyrinogen (Kirsch et al., 1998; Moore, 1998).
This study therefore investigated sequence variation in the ALAS and PBGD
genes as possible candidates for modifying the clinical expression in the South
African founder VP patients.
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1.4.2.1 ALAS
The 5-aminolevulinate synthase genes play a very important role in the haem
pathway as they are rate limiting for the entire synthetic process. In humans
and other mammals two ALA enzymes are present. These enzymes are
encoded by separate genes, ALAS-1 and ALAS-2, and are subject to different
forms of regulation. The catalytic domains of both isoforms are similar and
highly conserved between species, but their amino terminal regions differ
(Maguire et a/., 1986; Schoenhaut and Curtis, 1989; Conboy et al., 1992;
Yomogida et a/., 1993; May et ai., 1995; Duncan et a/., 1999). This results in
73% sequence conservation between the ALAS-1 and the ALAS-2 genes
(Ferreira, 1993).
ALA functions in the mitochondrial matrix but is initially synthesized as a larger
cytoplasmic precursor protein, which is proteolytically processed during the
transport phase into the mitochondria (May et ai., 1986). Haem can feed back
negatively and regulate its own synthesis by modulating the levels of ALA at
probably the translational level, through destabilizing the mRNA and by
blocking mitochondrial import (Srivastava et al., 1988; Drew and Ades, 1989;
May and Bawden, 1989; Hamilton et a/., 1991; Lathrop and Timko, 1993;
Zhang and Guarente, 1995).
ALAS-1 or ALAS-N, the so-called housekeeping gene, is located on
chromosome 3 and consists of 11 exons (Sutherland et ai., 1988). This gene is
expressed in all cells (Sutherland et al., 1988). The unprocessed precursor
ALAS-1 enzyme consists of 640 amino acids and has a molecular weight of
70580Da. ALAS-1 controls the rate of haem synthesis by its activity, which in
turn is determined by the amount of free haem in non- erythroid tissue.
The ALAS-1 promoter contains an array of regulatory elements including a
TATA-box. The promoter exhibits basal as well as tissue specific regulation and
contains binding sites for the nuclear respiratory factor 1 (NRF-1). This NRF-1
binding site, which is not present in the ALAS-2 promoter, is necessary for
basal expression. NRF-1 coordinates the synthesis of mitochondrial enzymes
engaged in the oxidative phosphorylation by regulating the ALAS-1 gene for the
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respiratory chain subunits. By the action of this transcription factor the gene is
expressed at a basal level in all tissue, but can be induced by a variety of
endogenous and exogenous factors.
No disease has yet been attributed to defects in the ALAS-1 gene (Elder, 1998;
Human gene mutation database http://www.hgmd.org [Krawczak and Cooper,
1997]). To date twenty single nucleotide polymorph isms (SNPs) have been
identified through the direct sequencing of the ALAS-1 gene (Bio-chip:
http://www.bio.chip.org/biotools/; Locuslink: http://www.ncbi.nlm.nih.gov/SNP/
[Maglott et al., 2000; Pruitt et al., 2000]) (See Table 1.2).
Table 1.2: The SNPs identified in the ALAS-1 gene
Nomenclature Area in gene
-5368 C>T 5' untranslated region
-5112 A>T 5' untranslated region
-4766 A>G 5' untranslated region
-4167 C>G 5' untranslated region
-3582 A>C 5' untranslated region
-2822 A>C 5' untranslated region
-2787 A>T 5' untranslated region
-1077 A>G 5' untranslated region
+604 A>T Intron 2
+946 C>T Intron 2
+2820 C>T Intron 2
+3505 C>T Intron 3
+4713 A>G Exon 4
+5399 A>G Intron 4
+5420A>G Intron 4
+7972 A>G Intron 7
+9645 C>T Intron 8
+12821 C>G Intron 9
+13853 C>T Intron 10
+14057 A>G Intron 10
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The human erythroid isoform ALAS-2 or ALAS-E is located on chromosome X
(Cox et aI., 1990). The structural organization of the ALAS-2 gene in the
human, mouse and chicken is very similar. The gene consists of 11 exons with
the presence of a 5-6kb intron in the 5'-untranslated region, being a unique
feature (Lim et al, 1994).
The unprocessed precursor enzyme consists of 587 amino acids, has a
molecular weight of 646930a, and is induced only during the period of active
haem synthesis in the red cells. Its activity in the cells is regulated by the
amount of free iron present. In the absence of iron, to be incorporated in the
porphyrin synthesized, the mRNA of the ALAS-2 gene is blocked by the
attachment of an iron-responsive element (IRE) binding cytosolic protein. The
transcription of this key enzyme is then inhibited. The IRE binding site is found
in the 5' untranslated region of the mRNA (May et al., 1990). ALAS gene
function is thus regulated at the transcriptional and the posttranscriptional level.
The control elements found in the ALAS-2 promoter region are very similar to
that found in the ~-globin promoter and the erythroid promoter of the PBGD
gene. This indicates control elements common to all three genes. The ALAS-2
gene was found to have a very low GC content and very few repetitive
elements (Surinya et a/., 1998).
To date eighteen single nucleotide polymorphisms have been identified through
the direct sequencing of the ALAS-2 gene (Bio-chip:
http://www. bio.chip.org/biotools/; Locuslink: http://www.ncbi.nlm.nih.gov/SNP/
[Maglott et aI., 2000; Pruitt et aI., 2000]) (See Table 1.3).
Table 1.3: The SNPs identified in the ALAS-2 gene
Nomenclature Area in gene
-5793 C>A 5' untranslated region
-4218 A>C 5' untranslated region
-3945 T>G 5' untranslated region
-3890 T>C 5' untranslated region
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-974 T>C 5' untranslated region
+1791 T>G Intron 3
+3297 T>A Intron 4
+5750 G>A Intron 6
+7133 T>C Intron 6
+7424 A>T Intron 6
+7630 T>A Intron 6
+7949 G>C Intron 6
+8163 T>C Intron 6
+10602 C>A Intron 8
+13583 T>C Intron 10
+14076 T>A Intron 10
+14449 A>T Intron 10
+16990 G>A 3' untranslated region
Mutations in the ALAS-2 gene were found to be the cause of types of X-linked
hereditary sideroblastic anemia. The patients present with features of a severe
anemia due to the impairment of hemoglobin formation, but show none of the
clinical or biochemical features associated with porphyria (Bottomley and
Muller-Eberhard, 1988).
1.4.2.2PBGD
The single copy PBGD locus is situated on chromosome 11q24 and the
complete genomic sequence, including the 5' regulatory, the 3' untranslated
and intronic regions has been published (Namba et al., 1991). The 10 024 bp
gene contains 15 exons ranging from 39 to 438 bp and 14 introns ranging from
87 to 2913 bp in size (Yoo et ai., 1993). PBGD cDNA has been cloned from a
variety of organisms, from E.coli to humans, and a high degree of conservation
is evident (Grandchamp et ai., 1996). the gene contains two promoter areas,
separated by 3kb of DNA, which give rise to two isoenzymes through
differential splicing (Lannfelt et ai., 1989).
The upstream promoter found at the 5' side of exon 1 is active in all cells and
produces mRNA that contains exon 1 and exon 3 through to exon 15.
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Translation of this mRNA produces a 44 kDa isoenzyme that differs from the
other isoenzyme by the addition of 17 amino acid residues at the NH2- terminus
(Deybach and Puy, 1987; Chretien et al., 1988; Voo et al., 1993). The minimal
non-erythroid promoter sequence for maximal transcription was found to be a
128 bp fragment containing nt-243 to nt-115, relative to the translation start site
(Lundin and Anvret, 1997). By implementing computer analysis, Voo et al.
(1993) found that this housekeeping promoter contained 10 Hpa il sites and
had a GC content of 54%. They also found two AP1 binding sites, both in the
antisense orientation at nt-491 to nt-487 and nt-126 to nt-119, and a AP4
binding site in the sense orientation at nt-461 to nt-456. A thyroid responsive
element (TRE) in the antisense orientation at nt-45 to nt-38 and two core
enhancer element (ENH) binding sites in the antisense orientation at nt-828 to
nt-821 and nt-16 to nt-89 were also found. Two SP1 elements at nt-201 to nt-
191 and nt-190 to nt-181 were present but no CAAT and TATA like promoter
elements were found. A CAC box at nt-33 to nt-29 in the sense orientation was
found and the presence of a 13 base repeat nt-243 to nt-217 was also
confirmed.
Erythroid-specific mRNA is produced from a promoter downstream from exon 1
and encodes exon 2 through to exon 15. A 42 kDa isoenzyme is formed
(Deybach and Puy, 1987; Chretien et a/., 1988). This promoter shows some
homology with the p-globin gene promoter and suggests that some common
transacting factors co-regulate the transcription of these genes during erythroid
development (Mignotte et a/., 1989). Studies done on the erythroid promoter
previously reported an AP1 site in the sense orientation at nt-2781 to nt-2788, a
CAAC motif in the sense orientation at nt-2839 to nt-2847, and a CAAT like box
in the sense orientation at nt-2855 to nt-2863. A TATA like element in the
sense orientation at nt-913 to nt-2918, two NF-E1 sites in both the sense
orientation nt-2760 to nt-2765, and the antisense orientation nt-2782 to nt-2790,
and a NF-E2 binding site at nt-782 to nt-2790 in the antisense orientation, have
also been investigated (Chretien et a/., 1988; Mignotte et a/., 1989; Frampton et
a/., 1990). Voo et al. (1993) found evidence of an additional four NF-1 binding
sites, three in the sense orientation (nt-2675 to nt-2679, nt-2713 to nt-2717, nt-
2724 to nt-2728) and one in the antisense orientation (nt-2827 to nt-2831).
They also found two topoisomerase (TOPO) binding sites, one in the sense
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orientation (nt-2332 to nt-2346), and one in the antisense orientation (nt-2329
to nt-2342). One AP4 binding site (nt-2830 to nt-2835) and one NF-E1 site (nt-
2573 to nt-2580), both in the sense orientation, were also present.
The PBGD enzyme is unique in the way that it uses two molecules of its own
substrate, porphobilinogen, covalently attached to the apoenzyme as a
prosthetic group (Shoolingin-Jordan et al., 1997). The PBGD reaction becomes
rate limiting when ALAS activity is increased (Moore et aI., 1987). Mutations
usually cause the PBGD activity to decrease to about 50% in all tissue, but
cases have been reported were the low enzyme activity was restricted to non-
erythropoietic tissue (Kappas et al., 1995). These cases could be explained by
mutations in the area upstream from the erythroid promoter that therefore
influences the housekeeping or ubiquitous form, but not the erythroid form.
Acute intermittent porphyria is the most common of the acute hepatic
porphyrias and is caused by mutations in the PBGD gene. AlP is an autosomal
dominant disorder and characterized by attacks of neurological dysfunction with
abdominal pain, hypertension, tachycardia and peripheral neuropathy (Kappas
et al., 1995). These attacks are caused by environmental factors such as
drugs and alcohol or endogenous factors, for example stress and hormones. In
the general population AlP specific mutations are found in about 0.6 per 1 000
individuals (Nordmann et al., 1997) but clinical manifestation of the disease is
less prevalent at about 1-2 per 100 000 (Kappas et al., 1995; Elder et al.,
1997). Of these individuals with an established AlP diagnosis, only about 10%
show a clinically manifest form, the remaining 90% remains latent throughout
their lives.
Extensive allelic heterogeneity is found in AlP patients and to date more than
165 mutations have been described (Grandchamp, 1998 for review; Whatley et
al., 1999(b); Human gene mutation database http://www.hgmd.org [Krawczak
and Cooper, 1997]). Found to be clustered in exons 10, 12 and 14 were 52% to
60% of the described mutations (Kaupinnen et al., 1995; Puy et al., 1997).
Only exon 2 has no reported mutations, because the transcript of the
housekeeping promoter does not contain exon 2, and exon 2 of the erythroid
specific transcript encodes no amino acids. Three mutations were also found
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to be relatively common in specific geographical areas and founder mutation
effects could explain this. These include the W198X mutation in Sweden, The
R116W mutation in Holland and the G111R mutation in Argentina (Lee and
Anvret, 1991; Gu et al., 1993; De Siervi et al., 1999). Homozygous AlP has
been described where the enzyme activity is less than 10% of the normal value.
No clear relationship between the type of mutation and the severity of the
clinical symptoms in AlP exists (Puy et al., 1997; Elder, 1998).
To date, sixteen polymorphic sites have been identified in the human PBGD
gene. Thirteen are characterized as intragenie SNPs and one is found in exon
10 but does not alter the amino acid sequence. Two polymorphisms exist in
the nonerythroid promoter region. Two polymorphic sites, a single base pair G
deletion at position 3167 in intron 2, and an A>G dimorphism at position 7052 in
intron 10, were only identified in a population consisting of African and Afro-
Caribbean individuals and never encountered in Caucasian subjects (Robreau-
Fraolini et al., 2000). The allele frequencies of the other 14 polymorph isms
found in the normal Caucasian population were almost identical to the allele
frequencies found in African and Afro-Caribbean control populations (Robreau-
Fraolini et al., 2000). A study of the allele frequencies of the four polymorphic
sites in intron 1, and the one polymorphic site in intron 3, concluded that they
exist in linkage disequilibrium (Yoo et aI., 1993). The nine remaining
polymorphic sites found in the Caucasian population were shown to segregate
independently (Robreau-Fraolini et al., 2000). These polymorphisms have
proven useful for heterozygote diagnosis in informative families whose
mutations were still unknown.
Table 1.4: The SNPs identified in the PBGD gene
Nomenclature Area in gene Method of Reference
detection
-235 A>T Promoter Direct sequencing Lundin and Anvret,
1997
-64 C>T Exon 1 ApaI Picat et al., 1991
+245 G>A Intron 1 MspI Llewellyn et al., 1987
+400 T>C Intron 1 Pst I Lee and Anvret, 1987
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+1277 C>A Intron 1 ApaLI Lee and Anvret, 1987
+2478 A>G Intron 1 BstNI Lee and Anvret, 1987
+3119 G>T Intron 2 DGGE Daimon et a/., 1993
+3167 G>deiG Intron 2 DGGE Robreau-Fraolini et
a/.,2000
+3581 A>G Intron 3 BsmAI Daimon et a/., 1993
+3982 T>C Intron 4 HhaI Whatley et a/., 1999b
+6479 G>T Exon 10 DGGE Gu et a/., 1991
+7052 A>G Intron 10 DGGE Robreau-Fraolini et
a/.,2000
+7064 C>A Intron 10 Hint I Yoo et a/., 1993
+7539 C>T Intron 12 Direct sequencing Whatley et a/.,
1999(b)
+7998 G>A Intron 14 MnLI Yoo et a/., 1993
+8578 G>A 3'UTR BsrI Law et a/., 1999
1.5 Sequence variation detection techniques
We rely on screening techniques to increase the efficiency in identifying unknown
mutations. To date quite a few protocols and procedures for the detection of
sequence variation exist, but none have been shown to be the ideal screening
procedure. The ideal screening procedure should have a 100% detection rate, be
inexpensive, not require expensive equipment with costly maintenance, should be
simple to the point that it is no more complex than conventional electrophoresis,
and it should allow for rapid analysis of large numbers (Ganguly, 2002).
1.5.1 Single strand conformation polymorphism (SSCP)
Single strand conformation polymorphism (SSCP) analysis is to date the most
widely used mutation detection technique and is based on the principle that
single stranded DNA assumes a distinct three-dimensional conformation. This
conformation is determined by the exact sequence of the fragment. The
conformation in return determines the rate at which a strand will migrate through
a nondenaturing polyacrylamide gel. Any change in the DNA sequence thus
alters the three-dimensional conformation and therefore the rate of migration
(Orita et a/., 1989). The resolution and the detection rate of mutations are
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determined by factors such as the temperature of the gel during electrophoresis,
the length of the gel, the percentage of glycerol in the gel matrix, the pH of the
buffer(s) and the size of the DNA fragment. The SSCP technique lacks the
theoretical background for exact secondary structure prediction (Glavac et al.,
2002) and the senisivity of unknown DNA fragments can therefore not be
determined in advance. Hayashi and Yandell (1993) estimated the detection
rate to be 90% in fragments shorter than 200 base pairs, and approximately 80%
in fragments up to 350 base pairs. A literature survey indicates that the
detection rate varies from 60% to 100% (Hayashi and Yandell, 1993; Ravnik-
Glavac et aI., 1994; Markoff et a/., 1998). The position of the base substitution
was shown to be more important than the precise nature of the base substitution,
in determining whether a mutation was detected (Sheffield et aI., 1993).
Although the detection rate of the SSCP technique is not 100%, it is still a rapid
procedure that can be automated. SSCP analysis does not require too highly
specialized skills and can also be used for high throughput applications
(Kristensen et al., 2001).
1.5.2 Heteroduplex analysis
Heteroduplex analysis is based on the formation of DNA duplexes that do not
match perfectly. DNA is heated and slowly cooled, so that the individual strands
may reanneal to complementary strands from either copy of the gene. If the
copies are identical, a perfect double helix (homoduplex) forms, but if the two
copies differ, as is the case when one copy harbors a mutation, a heteroduplex
forms. The migration rate of a heteroduplex and a homoduplex diffes in
polyacrylamide gels and a mutation can therefore be detected (Schreiber et a/.,
1995).
1.5.3 Conformation sensitive gel electrophoresis (CSGE)
Conformation sensitive gel electrophoresis is based on the proven assumption
that a system of mildly denaturing solvents can amplify the tendency of a single
base mismatch to produce conformational changes. The differential migration of
DNA homoduplexes and heteroduplexes during gel electrophoresis is thereby
increased (Ganguly et al., 1993). CSGE analysis is simple, requires no special
preparation of the PCR product, has a large capacity, and does not require
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radioactivity. CSGE was also shown to have a better detection rate than SSCP
analysis in a study by Markoff et al. (1998). Furthermore, CSGE detected all
previous mutations detected by denaturing gradient gel electrophoresis (DGGE)
analysis (Kórkko et al., 1998). Mutations in fragments between 200 to 800 base
pairs in length were shown to have a high detection rate with CSGE, although
mutations in unusually GC rich areas, and mutations at the 50 base pair ends of
heteroduplexes, showed a decline in their detection rate (Ganguly et al., 1993).
One previous drawback of CSGE was the inability to screen for homozygotes.
This problem was solved when Leung et al. (2000) developed a two-fold strategy
to detect homozygous sequence variants. This strategy is based on the creation
of artificial heterozygotes by preparing a mixture of the homozygous and wild
type PCR products in the ratio of 1:1 or 1:2.
1.5.4 Other screening techniques not used in this study
Direct sequencing of fragments was shown to be the most sensitive screening
technique available and, was even described as the 'gold standard' (Kirstensen
et al., 2001). In most laboratories manual sequencing, which is very time
consuming and labor intensive, has been replaced by automated sequencing
(Wen, 2001). Different automated systems are available and can either use four
different dyes to label each of the DNA bases, as in the case of ABI sequencing
systems, or alternatively in the Pharmacia-ALF sequencing technology, employ a
single dye chemistry format in which Cy5 is used to label DNA fragments for the
detection of laser-induced fluorescence (Kirstensen et aI., 2001). Both these
automated sequencing systems increased the turnaround time involved in
sequencing, but involve very high costs. This technology is therefore not suited
for small research laboratories, where the main aim is to seek sequence
variation in entire genes (Ganguly, 2002).
Denaturing gradient gel electrophoresis (DGGE) analysis is based on the melting
behaviour of double stranded DNA when exposed to increasing concentrations
of a denaturing agent (Lerman and Silverstein, 1987). Any change in the DNA
sequence of the fragment can affect the point at which the duplex will begin to
denature, which in turn slows its mobility in a polyacrylamide (PAA) matrix. The
PAA gel contains an increasing gradient of urea or formamide and is maintained
at a fixed temperature higher than room temperature. During the amplification of
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the fragment a 'GC-clamp', which consists of 30 to 40 bases of guanine and
cytosine, is added to improve the detection rate (Bourgeois et ai., 1992). DGGE
was shown to be more sensitive than HD and SSCP analysis, but is technically
very demanding.
Denaturing ion pair reverse-phase high performance liquid chromatography (D-
HPLC) is found to be rapid, robust and inexpensive (Oefner and Underhill, 1998).
This technique is based on the separation of heteroduplexes from homoduplexes
on a stationary phase under partially denaturing conditions. The D-HPLC
procedure can be automated and allows for the separation of ds DNA molecules
of up to 1kb in length. This technology is very useful to investigate genes with a
high frequency of point mutations at a variety of sites. The sensitivity of D-HPLC
was found to be between 95% and 100%, thus making it an extremely accurate
method for the detection of sequence variation (Liu et ai., 1998; O'Donovan et
a/., 1998; Ellis et ai., 2000; Le Maréchal et ai., 2001). Homozygous mutations do
not generally alter the stability of DNA fragments and therefore a mixture of PCR
products from the patient and a normal control is necessary to create
heteroduplexes for detection of different alleles in this procedure.
In the cases of DGGE and D-HPLC, a close prediction of the sensitivity and the
behaviour of the mismatches can be made from the theoretical melting curves
and the melting theory.
1.6 Statistical association analysis
Allelic association studies have proven to be a very effective way for locating
genes responsible for complex traits (Owen and McGuffin, 1993; Risch and
Merikangas, 1996). Association studies test whether a genetic marker
(polymorphism or allele) occurs more frequently in certain disease
cases/phenotype than in controls. The genetic marker can be associated with
either an increased or decreased risk. Association studies are better suited for
detecting genetic effects of low penetrance with higher resolution, and have
recently been successfully used to identify association between sequence
variation and different disease phenotypes in cases of Myasthenia gravis
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(Sciaccaet a/., 2002), late onset Parkinsons disease (Martin et aI., 2001) and
cutaneous basal cell carcinoma (Ramachandran et a/., 2001).
1.7 Aim of the study
The identification of modifier genes responsible for phenotypic variation in VP
could lead to a better understanding of the disease pathogenesis. Early diagnosis
and calculation of risk can lead to improved counseling and treatment and thus be
of great importance to VP individuals as well as clinicians attending to these
patients.
Attempts to identify variation in the PPOX gene itself, that could explain the
phenotypic variation observed in VP patients, have so far failed. Environmental
factors, for instance the influence of sunlight exposure, are very difficult to identify
and study due to the fact that it cannot be enforced or measured. In this study it
was thus decided to investigate sequence variation found in the genes that exhibit
a regulating function in the haem biosynthetic pathway. The hypothesis is
therefore that a mutation in the PPOX gene in combination with a mutation in one
of the rate limiting enzymes of the haem biosynthetic pathway would cause a
more severe phenotype. The rate of the entire pathway is determined by the
activity of the first enzyme ALA synthase, which is under negative feedback
control by the free haem. Secondary control is found at the level of PSG
deaminase, which is inhibited by proto- and coproporphyrinogen. The ALAS-1,
ALAS-2 and PBGD genes were thus investigated for their possible modifying
effect on the clinical symptoms found in VP patients.
To ensure a high detection rate of sequence variation in our population, three
different screening techniques, found to show high sensitivity in recent literature
reviews, were decided on (Ganguly et aI., 1993; Ravnik-Glavac et a/., 1994;
Kërkko et a/., 1998; Liechti- Gallati et a/., 1999). Sequence variants identified
would be subjected to statistical analysis to determine the existence of any
association.
Should any modifying influences or effects be found in the ALAS-1, ALAS-2 and
PBGD genes, their role in other porphyrias with low penetrance could also be
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determined. Ultimately this research could lead to the better understanding of the
haem pathway.
Specific aims of this study were:
1. To classify the R59W VP patients into four clinical groups (acute attack, skin
symptoms, acute attack and skin symptoms and asymptomatic).
2. To determine and compare the mutation detection rate of the three screening
methods SSCP, two buffer SSCP/HD and CSGE.
3. To compare the allelic frequencies of sequence variants in the ALAS-1, ALAS-
2 and PBGD genes in symptomatic and asymptomatic VP patients, and a
healthy control group
4. To investigate the existence of a possible statistical association between
sequence variants found in the ALAS-1, ALAS-2 or PBGD genes and the
clinical phenotypes of the South African VP population.
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Chapter Two
2 Materials and Methods
2.1 Patients
This study included 50 VP patients (37 women; 13 men; mean age 44; range 11-
71 years) of Afrikaner origin (white Caucasian ancestry). The diagnosis of VP was
based on the presence of the heterozygous R59W founder mutation. A
neurologist and dermatologist characterized 25 patients (group A) on their clinical
presentation. Group A also completed a clinical questionnaire attached as
Appendix A. The remaining 25 patients (group B) were characterized on the basis
of information contained in the clinical questionnaire previously completed by
themselves and a genetic counselor. Four groups were compiled consisting of a)
patients with skin symptoms, b) patients that had an acute attack (in clinical
remission at time of study), c) patients that show both skin symptoms and had a
previous acute attack and d) asymptomatic patients. Blood samples were
collected in tubes containing EDTA. Half of each blood sample collected was
sent, together with urine and stool samples, to a chemical pathology laboratory to
be analyzed for porphyrin and porphyrin precursors. The control group consisted
of 50 healthy unrelated Afrikaner individuals. Informed consent was obtained from
all participants under the guidance of the Ethics Committee of the Faculty of
Health Sciences, University of Stellenbosch.
2.2 Molecular Methods
2.2.1 Genomic DNA extraction from whole blood
Genomic DNA was extracted from whole venous blood using a standard protocol
adapted from Miller et al. (1988).
The blood was received in a 5ml EDTA (vacutainer) tube. The whole blood was
mixed with cold lysis buffer (0.155 M NH4CI; 0.01 M KHC03; 0.0001 M EDTA; pH
7.4) and left on ice for 15 minutes. The blood and lysis buffer mixture was
centrifuged for 10 minutes at 1500 g and 4°C. The supernatant was discarded
and the pellet mixed with PBS (phosphate buffered saline) (0.027 M KCI; 0.137
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M NaCI; 0.008 M Na2HP04; 0.0015 M KH2P04). After the solution was
centrifuged for 10 minutes at 1500 g and 4"C, the pellet was re-suspended in
nuclei lysis buffer (0.01 M Tris-HCI; 0.4 M NaCI; 0.002 M EDTA; pH 8.2), 10
mg/ml protease K and 20%(w/v) SOS. After an overnight incubation period at
37°C, 6 M NaCI2was added and the tube shaken vigorously for one minute. The
mixture was centrifuged for 15 minutes at 2500 g and 21°C and the supernatant
transferred to a clean tube, while leaving the pellet and foam behind. The
supernatant was again centrifuged for 15 minutes at 2500 g and 21°C. In a
fresh tube the gDNA in the supernatant was precipitated with two volumes of ice
cold 100%(v/v) ethanol. The gDNA was subsequently removed with a plastic
needle and placed in a clean 1.5 ml Eppendorf tube containing 70%(v/v) ethanol.
To wash the pellet, the Eppendorf tube was centrifuged at 14000g for 5 minutes
at 4°C. Afterwards the ethanol was removed and the pellet left to dry at room
temperature. The pellet was then dissolved in 500 j.ll of ddH20.
The concentration of the DNA was determined by loading an aliquot of the DNA
on a 1%(w/v) agarose gel in the presence of a low mass DNA ladder (Gibco).
1XTBE (5 X TBE: 89 mM Tris; 89 mM borate; 2 mM EDTA; pH 8.3) was used
as the running buffer. The gel underwent electrophoresis for an hour at 100V.
The fragments were visualized and captured using the Biorad 1000 Geldoc
system (Bio-Rad Laboratories) and the Scion Image software after staining with
ethidium bromide (EtBr) (1j.lg/ml).
2.2.2 Styl enzyme digestion
Most of the patients were identified from a database and were already
characterized as heterozygous for the founder R59W mutation. New patients
were molecularly characterized by using the PCR-RFLP protocol first decribed
by Warnich et al. (1996) incorporating the restriction enzyme Sty I (Promega).
A 234 bp fragment encompassing exon 3 of the PPOX gene was amplified by
PCR in a total volume of 25 ,..tl. The reaction mixture contained 30 ng template
DNA, 15 pmol of each primer, 200 ~M of each dNTP, 2.5 ~I 10X PCR
amplification buffer and 2 mM MgCI2. Half a unit (0. 1 ~I) of BlOTAQ DNA
polymerase (Bioline) was added to each reaction. The forward primer 5'-
TGCAGTGTCTCTCCCTCTTG-3' and the reverse primer 5'-
38
Stellenbosch University http://scholar.sun.ac.za
GCTCCCCT AAACTCTATTCC-3' were synthesized by Whitehead scientific. The
PCR amplification reactions were performed in a Perkin Elmer GeneAmp 9700
thermal cycler. The amplification profile involved 60 s at 95°C, followed by 10
cycles at 95°C for 30 s, 65°C for 45 s, 72°C for 30 s, and 30 cycles at 95°C for 30
s, 60°C for 45 s, 72°C for 30 s, with a final extention step at 72°C for 8 min.
The restriction digestion reaction consisted of 20 JlI of each PCR reaction, 2.3 JlI
of reaction buffer and 2JlI Sty 1(10 U/Jll) (Promega) enzyme. Digestion was done
overnight at 37°C according to the specifications of the manufacturer.
The restricted fragments were fractionated at 200 V on a 12%(w/v) (49: 1;
acrylamide: bis-acrylamide) Mighty Small (Hoefer) polyacrylamide gel for one
hour in the presence of a 100 bp DNA ladder (Promega) in 1.5XTBE (5X TBE
Buffer: 89 mM Tris; 89mM borate; 2mM EDTA; pH 8.3). Visualization took place
using the Biorad 1000 Geldoc system (Bio-Rad Laboratories) after staining with
EtBr (1Ilg/ml).
2.2.3 peR amplification of candidate genes
Each of the oligonucleotide primer pairs was designed to span not only the exon
of interest, but the flanking intron sequences as well to allow for the inclusion of
the splice junction.
Primer sets used for the amplification of the promoter and coding regions of the
ALAS-1, ALAS-2 and PBGD genes are listed in Tables 2.1, 2.2 and 2.3
respectively. The primer sequences for the PBGD gene were obtained from the
publication by Lundin and Anvret. (1997). Primers for ALAS-1 and ALAS-2 were
designed using the Primer Design V1.01 program. Three overlapping sets of
primers had to be designed for the promoter regions of both the ALAS-1 and the
ALAS-2 genes because of the size of these regions.
The PCR conditions were individually optimized for each exon or promoter
region and are listed in Tables 2.1, 2.2 and 2.3. The reaction mixture consisted
of 15 pmol of each primer, 200 IlM of each dNTP, 2.5 III 10X PCR amplification
buffer and 1-2 mM MgCI2. One III of genomic DNA at a concentration of 30ng/1l1
was used as the template. Half a unit (0.1 Ill) of BIOTAQ DNA polymerase
39
Stellenbosch University http://scholar.sun.ac.za
(Bioline) was added to each reaction. The final volume of the PCR reaction was
25 ul and the PCR amplification reactions were performed in a Perkin Elmer
GeneAmp 9700.
The three different PCR cycle programs implemented in the amplification of the
different regions were the following: The cycling conditions of program A
consisted of denaturation for 7 minutes at 94°C followed by 35 cycles of 94°C for
1 minute, ss-e for 30 seconds and 72°C for 1 minute, and the final step of 72°C
for 10 minutes (Lundin et al., 1995). The temperature profile for program B
commenced with 5 minutes at 94°C, followed by 30 cycles at 94°C for 30
seconds, 53°C-64°C for 30 seconds (depending on the Tm of the primers), 72°C
for 30 seconds, with a final extension at 72°C for 5 minutes. The amplification
profile for Program C was 5 minutes at 94°C, followed by 10 cycles at 94°C for
30 seconds, 53°C-65°C for 30 seconds (depending on the Tm of the primers),
72°C for 1 minute, and 30 cycles at 94°C for 30 seconds, 50°C-60°C for 30
seconds (depending on the Tm of the primers), 72°C for 1 minute, with a final
extension at 72°C for 5 minutes.
The amplified fragments were resolved by electrophoresis on a 1% agarose gel
in the presence of a 100 bp DNA ladder (Promega). Only single fragment
products, without any background, of the required size were subsequently used
for variation screening techniques.
2.2.4 Sequence variation detection methods
2.2.4.1 SSCP/HD protocol
A) The Conventional SSCP protocol:
Four jll of the amplified DNA fragments was denatured at 9aoC for 5 minutes in
the presence of 3 IJl loading dye (for 1 ml, mix 950 IJl Formamide, 1 IJl 10N
NaOH, 40 IJl 0.5 EDTA, 2.5 IJl 10%(w/v) Bromophenol blue and 2.5 IJl 20%(w/v)
Xylene cyanol)(Pan and Peng, 1997). The samples were immediately quenched
on ice and loaded on a 20%(w/v) poly-acrylamide gel. The ratio of the acrylamide
to
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Table 2.1: Primer sets and conditions for the amplificati-on of the promoter reqion as well as the
exonic regions of the human ALAS-1 gene from genomic DNA
Fragment PCR Annealing MgCI2 Program Forward Primer Reverse Primer
product Temperature (mM)
size (bp) (OC)
Promoter 324 N/A N/A N/A 5'-GAGACCTCGTCCGCCCAC -3' 5' -CACCTGCGCTGAGGACTG -3'
area 1
Promoter 272 N/A N/A N/A 5'-TCCATGTCCAAGACACCCAG -3' 5'-GGCAGAGAGGCCCACTTC -3'
area 2
Promoter 403 N/A N/A N/A 5'-AGCAAGGGGCTTCAGACAAC -3' 5'-AGTTGGGGGCTACAGGGTIG -3'
area 3
Exon 1 270 55 1 B 5' -CGAGCGTTICGTITGGACT -3' 5' -TAAACGCTGACCTCAAGG-3'
Exon 2 305 SS/SO 1 C 5'-TGCCTGATT ATT AACAACTGTTG-3' 5' -CCCAT ACCTGCTCCTTCATTG-3'
Exon 3 307 SS/SO C 5'-AACCAGATCTGATGCTTCAC-3' 5' -CCCTICACT ACCACT AATGG-3'
Exon 4 365 65/60 2 C 5' -GTGAACTAGGCCAT AAGC-3' 5' -GGA TI ACAGGT ATGAGCT AC-3'
Exon 5 294 SS/SO C 5'-TCACAACCATCA TICTGT ACTG-3' 5' -CAGT AATATTTGAAAGCCAAGG-3'
Exon 6 287 57/55 C 5'-GGGGAAAAAA TTCACATGGTG-3' 5' -AAACTCGAAGGCACTCATGC-3'
Exon 7 268 53 B 5' -TITGTCTTCGATGCACATGG-3' 5' -TTITICATCTTAGGTTTCAGAGG-3'
Exon 8 298 57/55 1 C 5'-GCTGTCTCCTCACCTGATCC-3' 5' -GCGGCAAAAGCTCTTCAGAG-3'
Exon 9a 222 57/55 1 C 5'-GGCTTCATCTTCACCACCTC-3' 5' -ACGGCAAGTCCAA TCAGAGA-3'
Exon 9b 229 58/55 C 5'-GGCTCCACAACACCTTGCTG-3' 5' -GCTCTTCAGGATCCGCACAG-3'
Exon10 234 SS/SO C 5'-GTGACCTT ACCTICTGCTCTC-3' 5' -AACTCCTCAGTGAGGCACCA-3'
Exon 11a 228 53/50 C 5' -CAAGTIGGTATCTGCTCAGGC-3' 5' -TAGCCACTGTGTCT AGCCAA TG -3'
Exon 11b 283 53/50 C 5'-ATGCTGCT ATGAACATTTGTGT A-3' 5'- TGAAA TAATTGAGGTCATGCTC -3'
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Table 2.2: Primer sets and conditions for the amplification of the promoter region as well as the
exonic regions of the human ALAS-2 gene from genomic DNA
Fragment PCR Annealing MgCI2 Program Forward Primer Reverse Primer
product Temperature (mM)
size (bp) (OC)
Promoter 316 53 1.5 8 5' -AGGAAGAGAAGAGTGTGGGTTC -3' 5' -AGATCCCCGGTTGTTGT AAC-3'
area 1
Promoter 304 53 1.5 8 5' -AAAGCACTT AGTGAAGGGTCTG-3' 5' -AGAGCTGGGATACCTTGAGC-3'
area 2
Promoter 371 53 1.5 8 5' -CCAACTTGTGCCACAGTC-3' 5' -GAGGACGAACGAA TGACAGG-3'
area 3
Exon 1 221 56 1 8 5' -CTAGCAAGGAAGGGACTGAG-3' 5' -GTACAGCCCTGAGAGACCAG-3'
Exon 2 322 56 2 8 5' -GAAGCTGAAGACGAGGATCA-3' 5' -CCCAGGACCCT AACA TTCTC-3'
Exon 3 322 56 2 8 5' -GGGACCAGACTCATCT ATCT -3' 5' -GTGACGT AGTGTGTTCAAGC-3'
Exon 4 287 56 2 8 5' -GTAGAAGCTGCCCTT ACCTT -3' 5' -CAGAA TGCCTTCCCT ATTCC-3'
Exon 5 306 54 2 8 5' -GCCAGGGAGAGACTT AAA-3' 5' -CACTGCTGATGGCTGAAA-3'
Exon 6 286 59 2 8 5'-CGATGCCTGACAAGAGTTTC-3' 5' -TGT ATTGCAGGAT ACCAGCC-3'
Exon 7 281 54 8 5' -AGGTTGAAGTGGGAGT AC-3' 5' -TTGTGAGACCAACACTAG-3'
Exon 8 281 56 8 5' -CATTGGAGATGGAGCTGG-3' 5' -TTGT AAGGGCCTCCTCTC-3'
Exon 9 355 56 8 5' -GGGACTGATT ATGGGATCTG-3' 5' -AATAGGTGGAGAGGGCAA TG-3'
Exon 10 268 55 1 8 5' -CAGAGTGGCAGGT ACT GATT -3' 5' -GCTTCTCTTICAGATCCTGG-3'
Exon 11 413 55 2 8 5' -GGCTCATCTGT ACTGTGACA-3' 5' -GGAGTCAGAA TGCACTTGTC-3'
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Table 2.3: Primer sets and conditions for the amplification of the promoter region as well as the
exonic regions of the human PBGD gene from genomic DNA
Fragment peR Annealing Mgel2 Program Forward Primer Reverse Primer
product temperature (mM)
size (bp) (Oe)
Promoter 661 64 1.5 B 5'-CAACAT AGTGAGGCCACCTCCCCGC-3' 5' -ACGACTGAGGATGGCAACCT -3'
area 1
Exon 1* 241 58 1.5 A 5'-GTCAGACTGT AGGACGACCT -3' 5' -ACGACTGAGGATGGCAACCT -3'
Exon 3 260 55 1.5 B 5'-TCCTTTCTTCCAAGCCAGTGA -3' 5' -CCACCCCATCTCCTTCAT AC-3'
Exon 4 191 58 1.5 A 5'-AAAGAGTCTGAGCCGTGGCT -3' 5' -TGTTCTCTCCTCTCGGGGT A -3'
Exon 5 272 58 1.5 A 5'-CCATCATGAA TCGT AGCACAG-3' 5' -TCATTCTTCTCCAGGGCATG -3'
Exon 6 229 57 1.5 B 5'-CCAGTTCTIGTCCCCACTCT -3' 5'-TAAGCCCAGCAGCCTATCTG -3'
Exon 7 286 55 1.5 B 5'-AGGCTCCACCACTGAAGT AG -3' 5' -CTCAGGGCAGAGGAGAT AAC -3'
Exon 8 215 58 1.5 A 5' -CCAGTGAGTTGGCCAA TCGAGA -3' 5' -CCTGCATCTICTGGGCACAT -3'
Exon 9 248 58 1.5 A 5' -TGCCCAGAAGATGCAGGGAT -3' 5' -CAGAGCCCTCTAGACCTIGT -3'
Exon 10 308 58 1.5 A 5'-GGGAAAGACAGACTCAGGCA -3' 5' -TGAACGT ATATCGCTITCACAC -3'
Exon 11 213 64 1.5 B 5'-GAACTCCCATCTCACTGCCA -3' 5' -TTCTGGGGAAGCAGATGCAG -3'
Exon 12 254 58 1.5 A 5'-GTCCCATGCTTICGGCCATT -3' 5'-ATCTICCCTGCCACCTTICC-3'
Exon 13 223 57 1.5 B 5' -CAGTGATGTCCTCAGGTCTG -3' 5' -GTCTGAGAGGGGACTACCT A -3'
Exon 14 233 58 1.5 A 5'-CTICCTGTGCAA TCCCAGGT -3' 5'-GGAGGTGGGA TITGGTGAGA -3'
Exon 15a 419 55/52 1.5 C 5' -TGCAGGCT ACCATCCATGTC-3' 5' -AGGCTIGAACCCTGCAGTIC -3'
Exon 15b 328 55/52 1.5 C 5'-TGCTGTCCAGTGCCT ACATC -3' 5' -GAACTCTGGGCAAAAGTCCC-3'
*Reasons for not including Exon 2 are given in Chapter 1, (1.4.2.2)
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the bis-acrylamide was 99: 1 and the dimensions of the Mighty Small (Hoefer) gel
used were 100 mm rw] x 105 mm [hJ x 0.75 mm [d]. The mixture for one gel of 10ml
is: 5 ml of 40%(w/v) acrylamide-bisacrylamide stock, 3 ml of 5XTBE, 2 ml of H20,
25 ~I of 25%(w/v) Ammonium persulphate (APS) and 10 jll of N,N,N',N'-
tetrametylethylenediamine (TEMED). Electrophoresis was performed for 4 hours at
200 Vand 15°C. The running buffer used was 1.5XTBE (89 mM Tris; 89 mM
Borate; 2 mM EDTA; pH 8.3). Silver staining (See 2.2.5) was implemented to
visualize the SSCP patterns.
B) The Two buffer SSCP/HD Protocol:
This protocol was obtained and adapted from the work done by Liechti-Gallati et
al. (1999).
Eight jll of the amplification product was mixed with 2 jll of loading dye (See
2.2.4.1. A) and denatured for five minutes at 98°C. The samples were
subsequently cooled on ice. A 12%(w/v) non-denaturing polyacrylamide gel with
a ratio of 99: 1 acrylamide to piperazine diacrylamide, PDA (Bio-Rad Laboratries)
was prepared. The mixture for one gel of 40 ml is: 12.5 ml of 40%(w/v)
acrylamide-PDA solution, 20 ml Tris-formate buffer (0.75 M, pH 9.0), 7 ml
41%(v/v) glycerol, 565 jll 1O%(w/v) APS and 56jll TEMED.
Electrophoresis was performed using a Dual slab Model #DSG-400 (C.B.S.
Scientific Co.) unit at 350 V for 2 hours and 15°C. The dimensions of the gel
apparatus used are 140 mm rw] x 360 mm [hJ x 0.75 mm [d]. The running buffer
was 1X Tris-formate buffer (0.75M, pH 9.0) and the trailing ion was Tris-borate
buffer (pH 9.0). EtBr staining (1jlg/ml) for 12 minutes was followed by UV light
exposure using the Biorad 1000 Geldoc System (Bio-Rad Laboratories). The
SSCP and HD images were captured using the Scion Image software.
2.2.4.2CSGE protocol
Fifteen jll of each PCR product was denatured at 98°C for 8 minutes and
subsequently incubated at 68°C for one hour to generate heteroduplexes. After
incubation the sample was mixed with 2 jll of loading dye (30%(v/v) glycerol,
0.25%(w/v) bromophenol blue, 0.25%(w/v) xylene cyanol) and kept on ice until
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loading. A standard 395 mm [w] x 335 mm [hJ x 0.75 mm [dJ DNA sequencing
gel apparatus (Model S2001, Life Technologies) was used in combination with a
40 well square tooth comb. A gel was prepared with 15%(w/v) polyacrylamide
(ratio of 99: 1 acrylamide to 1,4-bis [acryloyl]piperazine (Fluka) ), 10%(v/v)
ethylene glycol, 15%(v/v) formamide, 0.1%(v/v) APS and 0.07%(v/v) TEMED
with 0.5 X GT buffer (20% stock (250ml), combine 54 g Tris, 18 g Taurine, 1 g
Na2EDTA[pH9.0]). The electrophoresis buffer was also 0.5 X GT buffer. The
mixure for one gel of 120 ml is: 45 ml of 40%(w/v) polyacrylamide and 1,4-bis
[acryloyl]piperazine solution, 3 ml of 0.5 X GT buffer, 18 ml of formamide, 12 ml
of ethylene glycol, 40.8 ml of dH20, 82.8 ~I of TEMED and 1.2 ml of APS. The
gel was pre-run at 40W for 15 minutes before loading and the samples resolved
at 40W for 6 to 7 hours at room temperature. After electrophoresis the gel was
stained with EtBr (1~g/ml) for 12 minutes and visualized and captured using the
Biorad 1000 Geldoc System (Bio-Rad Laboratories) and Scion Image software.
2.2.5 Silver Staining
The gel was placed in a fixing solution (10% (v/v) ethanol, 0.5% (v/v) acetic acid)
for 10 minutes and afterwards rinsed in dH20 for approximately 1 minute. This
was followed by staining in 0.1% AgN03 for 10 minutes. A 5 second rinse with
dH20 was performed before developing the gel in a developing solution (1.5%
(w/v) NaOH, 0.155% (v/v) Formaldehyde) for about 10 minutes or until clear
bands were seen.
2.2.6 DNA sequencing
DNA fragments showing an abnormal ssep or eSGE pattern were purified with
the Qiaquick peR purification kit (Qiagen) according to the manufacturer, and
directly sequenced using the peR amplification primers and the ABI Prism Dye
Terminator Ready Reaction cycle sequencing kit. An ABI Prism 3100 genetic
analyzer (Applied Biosystems) was used. All the samples were sequenced in bi-
directionally and analyzed using the Sequence analysis 3.7 software (Applied
Biosystems).
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2.2.7 Restriction enzyme analysis of mutations
Restriction enzyme digestion was used to detect four of the six sequence
variations identified.
The ALAS-1 exon 4 fragment (See primers Table 2.1), 365 bp in length, was
digested with the enzyme Hsp92 IJ to identify the different alleles of the
polymorphism. The total volume of the reaction was 20 f..lland contained 0.2 f..ll
acetylated BSA (10 f..lg/f..ll),2 ul RE 10x Buffer, 10 f..llpeR product and 1 f..llof
enzyme (Promega) (10 U/f..ll).The final enzyme concentration in the total reaction
was thus 0.5 U/f..lland the reaction was incubated for 4 hours at 37°e to digest.
The alleles of the polymorphism in exon 1 of the PBGD gene could be identified
through the restriction of the exon 1 fragment (See primers Table 2.3) with Mnl]
The total volume of the digestion reaction was 20 ul and was prepared with 2 f..ll
10x Universal buffer, 10 ul of peR product and 0.5 f..ll of Mnl I enzyme
(Stratagene) (2U/f..lI).A final concentration of 0.05U/f.-l1enzyme was thus used in
an overnight digestion at 37°e.
In Intron 3 of the PBGD gene a polymorphism creates a site for the enzyme
Bsma I. The exon 4 region (See primers Table 2.3) of this gene which contained
this polymorphism, was subsequenctly amplified. The total restriction enzyme
reaction was 20 III and contained 2 III 10X NE buffer, 10 III peR product and 2 III
(5 U/Ill) enzyme (New England Biolabs). The final enzyme concentration was
0.5U/f.-l1. The digestion reaction was incubated at 55°e for 4 hours.
A polymorphism found in Intron 10 of the PBGD gene deletes a Hint I restriction
site. The primers of the exon 11 fragment of the PBGD gene were implemented
to amplify the region containing the polymorphism (See Table 2.3). The total
volume of the reaction was 20 f..ll and contained
1 f..ll(10 U/f..ll)Hint I enzyme (Roche diagnostics), 2 ul 10x Buffer and 10 ul peR
product. The final enzyme concentration was 0.5U/1l1. Digestion took place for 4
hours at 37°e.
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All the different fragments of the restriction enzyme digestion reactions were
fractionated on a 1.5% agarose gel in 1xTBE (5X TBE Buffer: 89 mM Tris; 89mM
borate; 2mM EDTA; pH 8.3) in the presence of a 100 bp DNA ladder (Promega).
Afterwards it was stained with EtBr (1!-lI/mi) and visualized and captured using
the Biorad 1000 Geldoc System (Bio-Rad Laboratories) and Scion Image
software.
2.3 Nucleotide numbering
In the interest of consistency in nomenclature and numbering, nucleotides are
numbered according to the recommendations of Den Dunnen and Antonarakis
(2001). The nucleotides of all three genes are numbered according to the cDNA
sequence derived from the genomic sequence taking the A of the ATG initiation
codon as +1.
The PPOX genomic sequence GI 1524086 (Puy et al., 1996) was used for all
references made to the PPOX gene. The ALAS-1 genomic sequence was still
unpublished at the time of the study and a PAC contig GI 4309923 which was
found to contain the ALAS-1 sequence was used as reference. The ALAS-2
genomic sequence GI 3220248 (Surinya et al., 1998) was used for all references
made to the ALAS-2 gene and the PBGD genomic sequence GI 292384 (Yoo et
al., 1993) was used for all references made to the PBGD gene.
2.4 Statistical analysis
Allele and genotype frequencies were calculated. The results were statistically
analysed by method of standard contingency tables and x2 analysis. Allelic and
genotypic associations were tested between the alleles/genotypes of the identified
sequence variations and the four clinical groups found in VP individuals and a
control group. The statistical significance for genotype/phenotype association was
taken as p< 0.05.
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2.5 Assessment of sequence homology
Database searches for homology were performed for the ALAS-1, ALAS-2. PBGD
and PPOX genes using the BLAST website (http://www.ncbi.nlm.nih.gov! BLAST!;
Altschul et aI., 1990), as well as the Homologene website
(http://www.ncbi.nlm.nih.gov!Homologenel).
BLAST 2 sequences (Tatusova and Madden, 1999) were utilised to compare the
exon 4 region (nt-4621 to nt-4771) of the human ALAS-1 gene (GI 4309923) with
the corresponding ALAS-1 gene sequences of the rat (GI 13324697) and the
chicken (GI 63040). The same comparison using BLAST 2 sequences was also
performed for the exon 10 region (nt-6372 to nt-6498) of the human PBGD gene
(GI 292384), comparing it to the rat PBGD sequence (GI 6981023) and the mouse
sequence (GI 200229).
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Chapter Three
3 Results and Discussion
Three genes ALAS-1, ALAS-2 and PBGD were selected as possible candidate
modifier genes for the clinical expression of VP on the basis of the regulatory
influence they have on the haem pathway. The potential modifier genes were
screened for sequence variation by means of three methods. The three screening
methods CSGE, conventional SSCP and two buffer SSCP were compared to
establish the method with the highest sequence variation detection rate and
reproducibility. Two of the six sequence variant sites detected were analysed in
the four extended clinicallly evaluated R59W VP patient groups, as well as a
control group. The results were statistically analysed to determine whether any
association exists between the different alleles of the polymorphic loci and the four
clinical groups.
3.1 Patients
At the planning stage of this study it became apparent that a well-defined group of
VP patients was crucial and quite a number of problems hindered this
characterisation process. The fact that some people had drugs administered while
others never came in contact with these medicines was an environmental
influence to consider. Some VP patients took precautions to minimize skin
ailments earlier than others, while some never applied any precaution to minimize
sun exposurel skin damage. The clinical expression of VP in patients also varies
with age as well as with the general clinical condition of the individual. People
demonstrate different symptoms while experiencing an acute attack and in certain
instances it was difficult to recognize if the individual indeed had had a porphyric
attack. With all these potential problems in mind, a dermatologist and a
neurologist each established protocols to characterize VP patients.
The neurological examinations assessed the effects of VP on the central and
peripheral nervous system. The methods used included a) a standardized clinico-
neurological evaluation involving assessment of activities of daily living (ADL)
utilizing Barthels index, b) nerve conduction studies of the upper and lower limbs
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(EMG) and c) autonomic function assessment. None of the 25 R59W patients
fulfilled the minimum criteria for the presence of a polyneuropathy, although 6
patients had a history suggestive of at least one acute visceral crisis, leading to
hospitalization in 4 cases (See Table 3.1).
Skin signs of VP include light and dark pathes, blisters, purple discoloration due to
bleeding, fragility, scarring and increased hair growth. At least three different skin
colours may be present in a single patient, especially in the advanced disease.
These are: whitish, shades of brown and purple. Individuals were assessed by
means of a medical examination during which the history of the patient was also
taken. A patient was concluded as having skin symptoms when he/she showed
positive results for any of the above-mentioned symptoms. The degree of the skin
symptom was also noted. Only one of the patients was diagnosed with blisters
while the other patients diagnosed with skin symptoms showed signs of scarring
and discoloration (See Table 3.1).
The 25 patients included in this study could not be characterized by means of their
biochemical results as the relevant laboratory has to date not completed the
testing of a normal control group to compare their results with. Without this
comparison it would be premature to decide what range of values would be taken
as a positive diagnosis for VP.
The distribution of clinical symptoms were in the same range when comparing our
clinical groups to previous studies performed by Eales et al. (1980) and Whatley et
al. (1999a) (See Table 3.1). This confirms the previous results found by Whatley
et al. (1999a) that the distrubution of clinical symptoms in the Western European
population is the same as the distrubution found in the South African population.
Although our R59W cohort is smaller than to the South African VP population
studied by Eales et al. (1980) the percentages of the clinical groups are very
similar. The only significant difference is found in the acute attack group, which
may indicate that VP patients are now less exposed to factors that could trigger an
acute attack than in 1980. These factors include the diagnosis at an early age with
the availability of genetic testing and the avoidance of precipitating factors as the
patients and medical docters are more informed about VP.
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Table 3.1: The comparison of results obtained from three different studies
indicating the distrubution of the clinical symptoms associated with VP
Symptom Result obtained Results from Results from
groups during this study. study conducted study conducted
by Eales et al. by Whatley et al.
(1980). (1999a)
Number % Number % Number %
Asymptomatic 8 32% NIA NIA NIA NIA
Skin 11 44% 156 52% 61 59%
symptoms
Acute Attack 2 8% 51 17% 20 20%
Both skin 4 16% 62 21% 22 21%
symptoms
and acute
attack
Biochemical NIA NIA 31 10% NIA NIA
Total 25 100% 300 100% 103 100%
3.2 Genomic DNA extraction
Genomic DNA extractions were performed within 24 hours after collection of the
blood samples. Samples of all DNA extracted underwent electrophoresis on a 1%
agarose gel in the presence of a low mass DNA ladder to determine the
concentration and to test for intactness of the samples. Concentrations of
between 30 ng/,.!! and 80 nglJ_!!were obtained. The original undiluted DNA
samples were stored at -80°C and the dilutions of 30 ngllli were aliquoted and
stored at -20°C.
3.3 Styl enzyme digestion
The R59W mutation causes a C to T transition in codon 59 of the PPOX gene that
creates a second Sty I enzyme-cutting site in the amplified fragment and results in
an arginine to tryptophan substitution (Meissner et a/., 1996; Warnich et aI., 1996).
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Digestion of the amplified 234 bp fragment in normal individuals results in two
fragments of 138 bp and 96 bp. In the case of heterozygous R59W VP individuals
digestion with the Sty I enzyme results in three fragments of 138 bp, 112 bp, 96 bp
respectively (See Figure 3.1). This is a rapid screening test, which has proved to
be very useful in the identification and genetic counseling of VP patients in South
Africa where the R59W mutation is frequent due to a founder effect (Meissner et
al., 1996; Warnich et al., 1996; UCT website: http://www.uct.ac.za/deptlliver/
index%20porphyria. htm).
3.4 peR amplification of candidate genes
Primer sets and conditions for the amplification of the PBGD gene were avaiable
(Lundin and Anvret, 1997), but primers had to be designed and optimized for the
amplification of the exons and promoter areas of the ALAS-1 and ALAS-2 genes.
These primers were all designed to include the exon/intron boundaries. The
amplified regions ranged in size from 191 bp to 661 bp (See Tables 2.1, 2.2, 2.3).
The promoter region of the PBGD gene was the largest fragment (661 bp) and a
SNP in the 5' untranslated area of the gene could be detected with the CSGE
method but not with the two SSCP methods. The same SNP was also not
detected with both the SSCP methods in a 241 bp fragment (See Table 3.2). The
majority of the fragments were smaller than 350 bp which is acknowledged to be
optimal for SSCP and CSGE analysis (See Tables 2.1, 2.2, 2.3). The optimal
length of fragments for CSGE analysis has been determined to be between 250
and 500 bp (Ganguly, 2002) and the optimal fragment length for SSCP analysis is
smaller than 350 bp (Hayashi and Yandell, 1993).
The only primers found to be problematic were those which encompassed the
promoter area of the ALAS-1 gene. The three sets of primers could never be
optimized to produce single amplicons. The primers were unsuccessfully
attempted in different combinations, including combinations with the primers of
exon 1. The genomic sequence for the ALAS-1 was obtained from a PAC contig
(GI 4309923), as no published genomic ALAS-1 sequence was available at the
time of the study. The genomic sequence is still unpublished. Different primer
design programs should be implemented when the sequence for this promoter
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area becomes available to attempt to amplification of this region with the minimal
formation of primer dimers.
Figure 3.1: The Sty I enzyme digestion of the fragment containing exon 3 of
the PPOX gene to identify all R59W patients
L1 L2 L3
112 bp fragment
• 96 bp fragment
Undigested 234 bp
fragment
138 bp fragment
Lane 1:
Lane 2:
100 bp DNA Ladder (Promega)
R59W positive individual, showing the
extra 112 bp fragment
R59W neaative individualLane 3:
Undigested fragments are seen due to the fact that a high amount of peR product was used
during the digestion procedure.
The amplification reactions incorporating the rest of the primers resulted in
products of the expected size. The amplified fragments obtained were of good
quality and sufficient quantity to perform further sequence variation detection
analysis.
3.5 Mutation detection techniques
Three PCR-based mutation-detection approaches were implemented to identify
sequence variation in the ALAS-1, ALAS-2 and PBGD genes. The SSCP (Orita et
al., 1989) detection technique was used as well as a modified version of the
SSCP/HD technique entitled the two buffer SSCP/HD mutation detection
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technique (Liechti-Gallati et a/., 1999). The third screening technique, CSGE, is
based on the differential migration of homoduplexes and heteroduplexes in mildly
denaturing solvents (Ganguly et aI., 1993).
A total of six sequence variant sites were identified in the three genes (ALAS-1,
ALAS-2 and PBGD) investigated (See Table 3.2 and 3.3). In the ALAS-1 gene a
previously described single nucleotide polymorphism 4713 T>C was identified in
exon 4. (Bio-chip:http://www.bio.chip.org/biotools/; Locuslink: http://www.
ncbi.nlm.nih.gov/SNP/ [Maglott et a/., 2000; Pruitt et a/., 2000]) (See Table 1.2).
The remaining of the five sequence variants were identified in the PBGD gene and
consisted of four previously described SNPs (-64 C>T; 3581 A>G; 6479 G>T;
7064 C>A) and one novel 8 bp deletion (4582_ 4589del) (See Table 1.4). No
sequence variation could be identified in the ALAS-2 gene using the three
screening techniques.
The 3581 A>G SNP and the 4582_ 4589del, both in the PBGD gene, and the 4713
T>C SNP in the ALAS-1 gene were the only sequence variation sites that could be
detected by the conventional SSCP technique. The two buffer SSCP technique
only facilitated the identification of two out of the six variation sites, namely the
3581 A>G SNP and the 4582_ 4589del in the PBGD gene. The CSGE method
detected the 4582_ 4589del as well as all the SNPs in both genes except for the
3581 A>G polymorphism in the PBGD gene. The latter variation was thus only
detected by the conventional SSCP and the two buffer SSCP techniques. The
4582_4589del deletion was the only sequence variation detected by all three
techniques.
The only SNP detected by SSCP analysis but which failed detection by the CSGE
technique (3581 A>G in the PBGD gene) was the one located nearest to the 5'
end of the PCR fragment (See Table 3.2). This sequence variant was found to be
less than 50 bp, i.e. 43 base pairs from the 5' end of the amplified fragment. The
other SNPs were found to be between 58 and 193 base pairs from either the 5'or
the 3' end. The 4582_ 4589del was detected with the CSGE technique although it
was only 37 bp from the 5' end of the fragment. It thus seems as if the position of
a deletion is not as important as the position of a SNP when the CSGE technique
is used.
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Table 3.2: The information concerning fragments in which sequence variant
were identified as well as information concerning the sequence variants
Gene Type of Position Fragment Base pairs
mutation of size from nearest
mutation 3'or5'end
ALAS-1 4713 T>C Transition Exon 4 367 bp 193 bp from 5'
end
PSGD -64 C>T Transition Exon 1 241 bp 59 bp from 5'
end
PSGD 3581 A>G Transition Intron 3 214 bp 43 bp from 5'
end
PSGD 4582_4589 Deletion Intron 6 286 bp 37 bp from 5'
del end
PSGD 6479 G>T Transversion Exon 10 308 bp 121 bp from 3'
end
PSGD 7064 C>A Transversion Intron 10 213 bp 58 bp from 5'
end
Although not many sequence variant sites were detected in this study, results
indicated that the position of the sequence variant had an influence on the CSGE
detection rate while the length of the fragment and the detection rate could not be
correlated with each other using any of the CSGE, SSCP or two buffer SSCP
techniques. From evaluating the three screening techniques, it was concluded that
the CSGE procedure had the highest detection rate (Five of six sequence
variants, 83%) for the three genes studied. The CSGE method facilitated the
identification of transitions and transversions in this study.
The CSGE method makes use of routine laboratory equipment and needs no
further manipulation of the PCR product. Although 1,4 Sis (acryloyl) piperazine
(SAP) is used, which is more expensive than some other cross-linkers, it was
shown to increase the gel conductivity and therefore give the gel more physical
strength compared to the same percentage acrylamide gels with the various other
cross-linkers, such as N'-N'-methylene-bisacrylamide (SIS) (Ganguly, 2002).
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Table 3.3: Results obtained with the three mutation detection techniques
CSGE SSCP Two buffer
SSCP/HD
ALAS-1
4713 T>C
PBGD
-64 C>T
PBGD
3581 A>G
+/- +/+ +/- +/-
+/+ +/- +/-
+/+ +/- +/-
+/- +/+
+/+ +/-
+/+ +/- +/+ +/-
PBGD
4582 4589del
+/- +/- +/+
+/+ +/- +/-
+/+ -/- +/- -/-
+/+ +/- +/- +/+
PBGD
+/- +/+
6479 G>T
+/- +/+ +/+ +/+ +/-
PBGD
7064C>A
+/- +/+ +/+
+/- +/+ +/- +/+
+ = wild type allele
- = variant type allele
Red squares indicate the screening method that successfully could discriminate between wild type and
variant alleles
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The degree of the altered migration of heteroduplexes is defined by both the
nature of a mutation and the position of the mutation with respect to the molecule
investigated (Ganguly et aI., 1993). Research has shown that the detection rate of
CSGE thus depends on the size of the PCR product as well as the location of the
mismatch in the PCR product (Ganguly et aI., 1993; Ganguly, 2002). For most
CSGE-based screening protocols, the optimal length of the PCR product was
found to be between 250 bp to 500 bp (Ganguly, 2002). Mismatches located
within 50 bp of the ends of the fragment were shown to have a low detection rate
and should be avoided (Ganguly et aI., 1993; Ganguly, 2002). It was also shown
that mutations in AT rich sequences are better resolved than those in G:C rich
context. The CSGE method was very successful in detecting
mutations/polymorphisms in the breast cancer type one (BRCA 1) and breast
cancer type two (BRCA2) genes, which is both very AT rich (Markoff et al., 1998).
Three mutations in the Type III procollagen (COL3A 1) gene were missed and later
found to be located in G:C rich high-melting domains (Ganguly et al., 1993). By
adding a short GC rich clamp to the end of PCR products and not observing any
rise in the detection rate, it was shown that the melting profile analysis alone can
not predict domains within a sequence that could give rise to false negative results
(K6rkk6 et aI., 1998; Ganguly, 2002). Results from this study correspond with the
results of Markoff et al. (1998) who also found that the CSGE had a higher
detection rate than the SSCP techniques.
In detecting sequence variants in the genes investigated, the conventional SSCP
technique proved to be superior (three of six sequence variants, 50%) to the two
buffer SSCP technique (two of six sequence variants, 33%) in our hands. All the
SNP identified with both the SSCP methods were classified as transitions and no
transversion were identified with the SSCP techniques during this study. The
original SSCP method was introduced by Orita et al. (1989) and is the most
extensively used mutation detection technique to date. The only other mutation
detection technique currently competing with SSCP is denaturing high
performance chromatography (D-HPLC) (Underhill et al., 1997; Xiao and Oefner,
2001; Glavac et aI., 2002). A disadvantage of the SSCP technique is that it lacks
the theoretical background for exact secondary structure prediction making the
optimisation procedure very difficult.
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3.6 ALAS-1 as a candidate modifier gene
The ALAS-1 gene was amplified and subjected to intensive investigation by all
three sequence variation detection techniques. Only one SNP was detected of a
total of 19 SNPs previously described in the ALAS-1 gene (See Table 1.2). These
19 SNPs were identified using direct sequencing. This information only became
available after we completed our variation screening procedures. Investigation of
the positions of the described SNPs revealed that only three (3505 C>T, 4713
A>G, 5420 A>G) were indeed found in the areas amplified during this study,
concluding that our detection teqniques failed to identify two of three possible
SNPs in the ALAS-1 gene. These SNPs, 3405 C>T and 5420 A>G were both
very close to the ends of the amplified fragments, 30 bp from the 3' end and 10 bp
from the 5' end, respectively. This could explain why they were not detected. No
information was provided on the allele frequencies of the SNPs or the study
population.
CSGE screening of the 367 bp fragment containing the ALAS-1 exon 4 region,
followed by automated sequencing of the PCR amplified genomic DNA, confirmed
the presence of a sequence variant site in exon 4 (See Figures 3.2, 3.3, 3.4 and
Table 3.4). The T>C sequence variant is located at nucleotide position 4713 in
exon 4 of the ALAS-1 gene. This 4713 T>C sequence variant creates a second
Hsp92 il restriction site site in the fragment which contains the exon 4 and
surrounding intron areas. The fragment containing the mutant C allele is cleaved
into 3 fragments (196 bp, 135 bp and 36 bp) while the T allele is only cut once into
two fragments (331 bp and 36 bp)(See Figure 3.5).
Figure 3.2: Structure of ALAS-1 gene and the location of the 4713 T>C SNP
1 2 3 4 5 6 7 8 9 10 11
4713 T>C
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Table 3.4: Partial gDNA sequence of the amplified region containing exon 4
of the ALAS-1 gene indicating the position of the 4713 T>C SNP
gtgaactagg ccataaga::a tttttgacaa tatgtttgga agatattgtg
aactcagaat agaaagttgg tcccatttgt ttcttgttac ttttgttcca
gAGGTTGCTG AAACCTCAGC AGGCCCCAGT GTGGTTAGTG TGAAAACCGA
TGGAGGGGAT CCCAGTGGAC TGCTGAAGAA CTTCCAGGAC ATTATGCAAA
AGCAAAGACC AGAAAGAGTG TCTCATCTTC TTCAAGATAA CTTGCCAAAA
Tgtaagtctc attgttattt gcctgatgta gaaaagaatt tataattcaa
atgtacatta gattaaatat aaaattgcat ggtgaggctg ggcacagtag
ctcatacctg ttaatcc
Partial gDNA sequence obtained from PAC contig accession number G14309923. The exon
4 region is indicated by capital letters while the surrounding intron areas are given in
lowercase letters. The sequence of the forward primer and reverse primer are indicated in
blue. The site of the 4713 T>C polymorphism is indicated with bold font and underlined.
Figure 3.3: A CSGE gel photo indicating the different migration patterns of
the heteroduplexes and homoduplexes of the exon 4 fragment of the ALAS-1
gene
L1 L2 L3 L4
Lane 1:
Lane 2 to 4:
Homozygous individual (TT or CC)
Heterozygous individuals (TC)
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Figure 3.4: Results obtained from the automated sequencing in the sense
direction of the ALAS-1 fragment of a heterozygous individual containing
the 4713 T>C polymorphism
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The arrow indicates the exact position of the 4713 T>C
polymorphism
Figure 3.5: A 1.5% Agarose gel showing the different alleles of the 4713T>C
polymorphism in the ALAS-1 gene after digestion with the restriction
enzyme HSP92 II
135 bp
Li L2 L3 L4 L5 L6
196 bp III>
Lanes 1,4,5:
Lanes 2 and 6:
Lane 3:
CC homozygotes
TC heterozygotes
TT homozygote
The 36 bp fragment is not visible on this gel, due to it's increased migration rate,
The allelic frequency for the 4713 T>C sequence variant was found to be T=
0.49; C= 0.51 in 49 VP patients and the frequency found in the normal control
group of 50 was T= 0.52; C= 0.48. Statistical analysis was performed for the
smaller well characterized group A of 25 as well as for the combined group (A
and B)
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comprising 49 individuals (See Tables 3.5 to 3.6). The Chi Square value for
group A was calculated as 10.136 and the probability p= 0.2556 when comparing
the genotypes of the 4713 T>C SNP with the four clinical groups and a control
group of 50 individuals. The Chi Square value was calculated to be 5.369 and
the probability p=0.717 when comparing the genotypes of the same SNP with
the four clinical groups and the control group using the combined group (A and
B) (See Tables 3.5 and 3.6). No statistical significant association was
demonstrated between the genotypes and any of the VP symptom groups.
Table 3.5: Contingency Table of the 4713 T>C polymorphism data generated
for the group A VP patients and the control group
Group
No symptoms
Acute Attack
Skin lesions
Acute attack and Skin lesions
Controls
Total
Chi Square value:
Probability:
Observed Genotype
TIT TIC CIC Total
3 2 2 7
1 0 1 2
4 5 2 11
0 4 1 5
9 34 7 50
17 45 13 75
10.136
0.256
Table 3.6: Contingency Table of the 4713 T>C polymorphism data generated
for the group A and group B VP patients and the control group
Group
No symptoms
Acute Attack
Skin lesions
Acute attack and Skin lesions
Controls
Total
Chi Square value:
Probability:
5.369
0.717
Ob dGserve enotype
TIT TIC CIC Total
4 7 3 14
1 3 1 5
5 8 4 17
1 8 4 13
9 34 7 50
20 60 19 99
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A homology search of the human ALAS-1 gene (GI 4309923) and Rattus
norvergicus aminolevulinic acid synthase 1 mRNA (GI 13324697) was conducted
using the BLAST 2 sequences program (http://www.ncbi.nlm.nih.gov/blast;
Tatusova and Madden, 1999)(See Figure 3.6). The same homology search was
applied to the human ALAS-1 gene and the chicken gene for mt 5-
aminolevulinate synthase exons 1-7 (GI 63040)(See Figure 3.6). The area under
investigation, exon 4 nt 4621 to nt 4771 of the human ALAS-1 gene, revealed
significant homology between both the rat and chicken ALAS-1 genes.
Sequence alignment analysis revealed that the rat ALAS-1 gene 448 to 599 had
an 81% homology with the human ALAS-1 gene nt 4619 to nt 4770, while the
ALAS-1 gene of the chicken 3057 to 3149 had 86% homology with the human
ALAS-1 gene nt 4684 to nt 4776.
The region encompassing surrounding the exon 4 polymorphism is conserved
with the C allele present in the rat sequence and the T allele present in the
chicken sequence. The high degree of conservation found between these three
species probably points to the biological significance of the ALAS-1 gene in the
haem biosynthetic pathway.
Figure 3.6: Sequence alignment of the human exon 4 region of the ALAS-1 gene
with the rat ALAS-1 mRNA and the chicken ALAS-1 mRNA
Homo sapiens: (nt 4619) (nt 678)
Rattus norvegicus:(448) (507)
(nt 4679)
(567 )Rattus norvegicus: (508)
Homo sapiens: (nt 4738)
Chicken: (3055)
Rattus norvegicus: (568) (599)
Homo sapiens: (nt 4739) (nt 4770)
Chicken: (3111) (3143)
Regions of homology with the human ALAS-1 sequence are indicated in blue and highlighted in grey. The
polymorphism identified in the human ALAS-1 gene at position 4713 is highlighted in purple.
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This sequence variant changes codon 173 from AUU to AUC, both encoding the
amino acid isoleucine. This nucleotide substitution is thus regarded as a silent
mutation because both the wild-type and the mutant alleles encode the same
amino acid. However, silent mutations can cause phenotypic variability by
influencing the splicing accuracy or efficiency (Cartegni et a/., 2002). A silent
mutation has been shown to induce post-transcriptional exon skipping in the case
of phenylketonuria (PKU [MIM 261600]) where the c1197 A>T substitution results
in the skipping of exon 11, leading to a PKU phenotype (Choa et a/., 2001). The
exon 11 skipping event, induced by the SNP, results in a frame-shift mutation with
the replacement of the C-terminal 97 residue segment with 21 missence codons,
followed by a premature stop codon in exon 12.
The exon skipping mutation mechanism is usually caused by changes in the
consensus sequence at splice sites or the lariat branch point region, but
sequences outside these regions may also effect the inclusion or exclusion of
exons. The silent mutation C6354T in the Fibrililin -1 (FBN-1) gene found in
individuals with Marfan syndrome (MFS) is unlikely to affect known binding sites
as it is located 26 bp upstream of the 3' splice site and 6 nucleotides downstream
from a purine rich potential exon recognition sequence. The results of different
types of expression constructs, however confirmed that the skipping of exon 51 is
solely due to this silent mutation (Liu et al., 1997).
To demonstrate the influence of penetrance, or the disease-causing potential of a
silent mutation through abnormal splicing, in vivo studies need to be carried out
by using an exon-trapping expression vector, which falls outside the scope of this
study.
3.7 ALAS-2 as a candidate modifier gene
No sequence variation was identified in the ALAS-2 gene in our VP cohort using
the three mutation screening techniques. A total of 18 SNP has been described in
previous studies through direct sequencing (See Table 1.4). Only one (8163 T>C)
of these decribed polymorphims was situated in the region of the ALAS-2 gene
that we amplified and subjected to sequence variation analysis in this study. None
of the three sequence variation detection techniques, however, detected this
polymorphism. This SNP is located 43 bp from the 5' end of the amplified
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fragment that contained exon 7. Once again this SNP will likely not be detected
by the CSGE method according to Ganguly et a/., (1993). No information is
available on the allele frequencies of the SNPs or the study population.
Introns 1, 3 and 8 correspond to Dnase I hypersensitivity sites in the structurally
related mouse ALAS-2 gene (Schoenhaut and Curtis, 1989). Dnase I
hypersensitive sites are indicative of nucleosome free regions of DNA associated
with transcription regulatory factors (Elgin, 1988; Gross and Garrard, 1988).
Surinya et a/. (1998) investigated the effect these three regions might have on the
expression of the gene. Preliminary results indicated that the intron 3 (850 bp)
region had an inhibitory effect and bath the intron 1 (4.9 kb) and the intron 8 (460
bp) regions had a stimulatory effect on the promoter activity. Intron 8 had the
most significant increase in the promoter activity and was thus chosen for further
investigation. The erythroid specific enhancer region in intron 8 was found to be
localized to a 239 bp region. Results illustrated that a GATA-1 binding site and
two CACCC boxes are located within this region. These binding sites are
conserved across species and are critical for the erythroid-specific enhancer
activity in transfected erythroid cells. T0 date no sequence variations, have been
described in the intron 1 region, but at the end of 2001, a list of polymorphisms
was published on the internet websites Bio-chip:http://www.bio.chip.org/biotools/
and LocusLink: http://www.ncbi.nlm.nih.gov/SNP describing SNPs in both the
intron 3 (1791 T>G) and the intron 8 (10602 C>A) regions. It will be very
interesting to investigate in future studies whether these two polymorph isms are
present in our population and whether they are indeed associated with a clinical
phenotypic group of VP.
3.8 PBGD as a candidate modifier gene
Twelve of a total of 16 described polymorphisms in the PBGD gene were located
in the areas that were investigated. Of these twelve (-235 A>T, -64 C>T, 3119
G>T, 3167 D>Del, 3581 A>G, 3982 T>C, 6479 G>T, 7052 A>G, 7064 C>A, 7539
C>T, 7998 G>A, 8578 G>A) (See Table 1.4 for detection techniques) only four (-
64 C>T, 3581 A>G, 6479 G>T, 7064 C>A) were detected in this study. Seven of
the eight SNPs not detected were located closer than 50 bp from either the 5' or 3'
end of the amplified fragment. The 3119 G>T SNP was located 1 bp from the 3'
end, the 3167 D>Del was 47 bp from the 5' end, the 3982 T>C SNP was 22 bp
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from the 5' end, the 7052 A>G SNP was 46 bp from the 5' end, the 7539 C>T
SNP was located 10 bp from the 3' end, the 7998 G>A SNP was located 48 bp
from the 5' end and the 8578 G>A SNP was located 23 bp from the 3' end of the
amplified fragment. The -235 A>T SNP was 380 bp from the 5' end and 281 bp
from the 3' end, but the amplified fragment may have been too large to detect this
SNP. The SNPs not detected were previously described by means of direct
sequencing, DGGE analysis and through the use of specific restriction enzymes.
The 3167 D>Del in intron 2 and the intron 10 polymorphism, 7052 A>G were only
identified in an Afro-Caribbean and an African population group. These two
polymorphisms were not encountered in 750 unrelated Caucasian individuals,
which could explain why they were not found in our population (Robreau-Fraolini
et al., 2000). The four described intron 1 SNPs (1345 G>A, 1500 T>C, 2377 C>A,
2479 A>G) were not located in the areas that were amplified and investigated, but
were shown to be in marked linkage disequilibrium with the intron 3 polymorphism
3581 A>G in both the Northern American Caucasian and the Northern European
population (Lee and Anvret, 1991; Yoo et al., 1993). The intron 2 polymorphism of
the PBGD gene 3119 G>T has demonstrated a wild type allele frequency of 0.95
and a mutant allele frequency of 0.05 in 78 Caucasians and a wildtype allele
frequency of 0.97 and mutant allele frequency of 0.03 in an Afro-Caribbean and an
African population population group of 98 individuals (Robreau-Fraolini et aI.,
2000). The allele frequencies of the intron 12, 7539 C>T, polymorphism in these
two populations was found to be C=0.87 and T=0.13 and C=0.97 and T=0.03
respectivily (Robreau-Fraolini et al., 2000). The common G allele of the 7998 G>A
polymorphism in intron 14 was found at an allele frequency of 0.97 in 96 normal
American Caucasians. The allele frequency of the A allele is thus 0.03. The
possibility therefore exists, that our screening population was likely too small to
detect these three rare polymorph isms. It could also be that the non-identified
polymorphisms are not presenUfound in the specific population that was
investigated. The close proximity to the ends of the amplified fragments of some
of the non-detected SNPs could explain the false negative results found with the
CSG E protocol.
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Four previously described polymorphic sites were identified in the VP patient-
screening group (See Figure 3.7). They include the -64 C>T polymorphism in
exon 1 (Picat et aI., 1991), the 3581 A>G polymorphic site in intron 3 (Daimon et
aI., 1993), the 6479 G>T polymorphic site in exon 10 (Gu et aI., 1991) and the
7064 C>A polymorphism in intron 10 (Yoo et al., 1993). A novel 8 bp deletion,
4582_ 4589del, was also identified in our population (See Figure 3.7). Homology
searches to determine the conservation of areas containing the sequence
variation sites found in the PBGD gene, could only be done for the exon 10 6479
C>T polymorphism. The other sequence variation sites were found in intronic
areas or, in the case of the exon 1 -64 C>T polymorphism, in the 5' untranslated
region for which sequences of other species are still unavailable or not yet
released.
Figure 3.7: Structure of the PBGD gene and locations of sequence variant
sites identified in this study
1 789 10 11121314152 3 4 5 6
-64C>T 3581 A>G 4582_4589del 6479 G>T 7064 C>A
3.8.1 The -64 C>T polymorphism in exon 1 of the PBGD gene
Screening of the 241 bp fragment containing exon 1 of the PBGD gene resulted in
the detection of the -64 C>T SNP. After detection with both the CSGE and SSCP
methods, the presence of the SNP was confirmed with sequencing (See Table 3.7
and Figure 3.8).
The C>T polymorphism upstream from exon 1 was previously detected by the use
of a 5'-primer, with a mutated sequence. Together the mutated primer and the
polymorphic base C create an Apa I restriction site (Picat et al., 1991). Our
research proved that the restriction enzyme Mnl I instead of the preceding
mutated primer could be used for identifying this polymorphic site (See Figure
66
Stellenbosch University http://scholar.sun.ac.za
3.9). The fragment containing the wildtype allele has no recognition site for the
Mnl I enzyme, whereas the mutant allele has a recognition site for the Mnl I
enzyme resulting in the cleaving of the 214 bp fragment into fragments of 175 bp
and 39 bp. This polymorphism is found close (-64) to the 3' splice site of the
promoter area, but thorough investigation by Voo et aI., (1993) not form part of
any transcription factor binding or splice site (See Chapter 1.4.2.2).
Table 3.7: Partial gDNA sequence of the amplified region containing exon 1
of the PBGD gene indicating the position of the -64 C>T SNP
gtcagactgt aggacgacct cgggtcccac gtgtccccgg tactcgccgg
ccggagcc_!:c cggcttcccg gggccggggg accttagcgg CACCCACACA
CAGCCTACTT TCCAAGCGGA GCCATGTCTG GTAACGGCAA TGCGGCTGCA
ACGGCGgtga gtgctgagcc ggtgaccagc acactttggg cttctggacg
agecgtgeag cgattggccc caggttgcca tcctcagtcg t
Partial gDNA sequence obtained from genomic sequence Accession number G1292384.
The exon 1 region is indicated by capital letters while the surrounding intron areas are given
in lowercase letters. The sequence of the forward primer and reverse primer are indicated in
blue. The site of the -64 C>T polymorphism is indicated with bold font and underlined.
Figure 3.8: Results obtained from the automated sequencing in the sense
direction of the PBGD gene fragment containing the -64 T>C polymorphism
in a heterozygous individual
The arrow indicates the exact position of the -64 T>C polymorphism
67
Stellenbosch University http://scholar.sun.ac.za
Figure 3.9: A 1.5 % agarose gel showing the banding patterns of the PBGD
exon 1 polymorphism after digestion with restriction enzyme Mnl I
M L1 L2 L3 L4 L5 L6
200 bp
214 bp
175 bp
Lane M:
Lane 1:
Lane 2-5:
Lane 6:
100bp DNA ladder
TT homozygous individual
CT heterozygous individuals
CC homozygous individual
The allelic frequency for the --64C>T polymorphism from 35 unrelated individuals
of European Caucasoid origin T=0.37; C=0.63 (Picat et al., 1991) were identical
to that of 78 non-porphyric Caucasoid unrelated individuals from the Centre
d'Etude du Polymorphisme Humain (CEPH, Paris, France) (Robreau-Fraolini et
al., 2000). The allelic frequency found in our 42 VP patients (group A and B
combined), differed only slightly T=0.42; C=0.58. No association of statistical
significance could be demonstrated between the --64 C>T polymorphism
genotype and any of the clinical symptoms associated with VP (See Tables 3.8
to 3.9). (l= 2.82; p= 0.945). The Chi square value for Group A and B was
3.054 and the probability 0.931. These results could be due to the limited
number of VP patients, especially the acute attack group. However, if the
polymorphism had a major influence on the clinical expression, it would most
likely have been noticable in this small group.
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Table 3.8: Contingency Table of the -64 C>T polymorphism data generated
for the group A VP patients and the control group
Group
No symptoms
Acute Attack
Skin lesions
Acute attack and Skin lesions
Controls
Total
Chi Square value:
Probability:
2.821
0.945
Observed Genotype
CIC CIT TIT Total
3 3 1 7
1 1 0 2
3 5 3 11
3 1 1 5
17 20 7 44
27 30 12 69
Table 3.9: Contingency Table of the -64 C>T polymorphism data generated
for the group A and group B VP patients and the control group
Group
No symptoms
Acute Attack
Skin lesions
Acute attack and Skin lesions
Controls
Total
Chi Square value:
Probability:
Observed Genotype
CIC CIT TIT Total
5 4 2 11
2 2 0 4
4 6 4 14
4 7 2 13
17 20 7 44
32 39 15 86
3.054
0.931
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3.8.2 The 3581 A>G polymorphism in intron 3 of the PBGD gene
Both the SSCP methods facilitated the detection of the 3581 A>G polymorphism
in the exon 4 amplified fragment of the PBGD gene (See Table 3.10 and Figure
3.10). The 191 bp fragment was subjected to sequencing to confirm the
presence of this SNP.
When the mutant G allele is present, Bsm AI cuts the 191 bp fragment
containing the 3581 A>G polymorphism. This results in two fragments of 144 bp
and 47 bp (See Figure 3.11).
The allele frequency in a normal American Caucasian group of 100 individuals
was found to be A=0.59 and G=0.41 (Yoa et al., 1993). The allele frequency in
78 Caucasians (non-porphyric white unrelated families from the Centre d' Etude
du Polymorphisme Humain, CEPH, Paris, France) was G=0.75 and A=0.25. The
frequency in 30 Afro Caribbean individuals were G=0.79 and A=0.21 and the
frequency in 68 African individuals were found to be G=0.85 and A=0.15
(Robreau-Fraolini et al., 2000). Oue to a time and financial constraint this SNP
was not investigated in our extended VP group or in the control group.
Table 3.10: Partial gDNA sequence of the amplified region containing exon 4
of the PBGD gene indicating the position of the 3581 A>G SNP. (In 5'- 3'
direction)
aaagagtctg agccgtggct gggaagggca ggactaatcc aaatctctac
ccgcagCTTG CTCGCATACA GACGGACAGT GTGGTGGCAA CATTGAAAGC
CTCGTACCCT GGCCTGCAGT TTGAAATCAg tgagttttct ggaaaggagt
ggaagctaat gggaagccca gtaccccgag aggagagaac a
Partial gDNA sequence obtained from gDNA sequence Accession number GI 292384. The
exon 4 region is indicated by capital letters while the surrounding intron areas are given in
lowercase letters. The sequence of the forward primer and reverse primer are indicated in
purple. The site of the 3581 A>G polymorphism is indicated with bold font and underlined.
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Figure 3.10 : Results obtained from the automated sequencing in the
antisense direction (3'-5') of the PBGD gene fragment containing the 3581
A>G polymorphism in a heterozygous individual
G C (__ G'
o
The arrow indicates the exact position of the 3581 A>G
polymorphism
Figure 3.11: A 1.5% agarose gel showing the various homozygous and
heterozygous banding patterns of the intron 3, 3581 A>G polymorphism
after digestion with BsmAl
M Li L2 L3 L4 L5 L6
191 bp
144 bp
M:
Lane 1 to Lane 4:
Lane 5:
Lane 6:
100 bp DNA ladder
AA homozygous individuals
GG homozygous individual
AG heterozygous individual
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3.8.3 The 4582 4589del in intron 6 of the PBGD gene
During the course of this study a novel 8 bp deletion was detected in intron 6.
(See Table 3.11). The deletion was observed with all three sequence variantion
detection techniques and confirmed by the sequencing of the 286 bp fragment
(See Figures 3.12 and 3.13). The 4582_ 4589del site was initially detected in 3
of 25 individuals. Two of the three individuals with the deletion were related
(mother-daughter). We were not able to analyze more individuals during this
study for the 4582_ 4589del, due to finacial and time constraints. When a larger
characterized VP group is available the influence of this deletion should be
further investigated. The two related patients were, while the third individual had
skin symptoms. All three were from Group A (characterized by the neurologist
and dermatologist).
In higher eukaryotes at least three sequence elements participate in the initiation
of the splicing reaction viz. the 5' splice site, the 3' splice site consensus
sequence and the RNA branchpoint (Ruskin and Green, 1985). Mutations of
these sequences may cause abnormal gene expression (Cooper and Mattox,
1997), The 4582_ 4589del deletion is located close to the 3' splice site (-51) but
does not contain sequences that are considered to be involved in the splicing
process. However, further expression studies will have to be performed to
determine with confidense wheter or not this mutation has any influence on the
splicing process.
Table 3.11: Partial gDNA sequence of the amplified region of exon 7 of the
PBGD gene indicating the position of the 4582_ 4589del
aggetecace actgaagtag aggcaggggt gggtggagaa ggggtgaagg
ctggctgctc ataccctttc tctttgcccc cctctcccat etctatagAG
TGGACCTGGT TGTTCACTCC TTGAAGGACC TGCCCACTGT GCTTCCTCCT
GGCTTCACCA TCGGAGCCAT CTGCAAgtaa gagtcttgca agtaaggggc
ttgggcaggg gtaggcatca tgtgaacctt tgcctttccc tttggggcct
gaccctctgc ttcagggtta tctcctctgc cetgag
Partial gDNA sequence obtained from gDNA sequence Accession number GI 292384. The
exon 7 region is indicated by capital letters while the surrounding intron areas are given in
lowercase letters. The sequence of the forward primer and reverse primer are indicated in
blue. The site of the 4582_ 4589del deletion is indicated with bold font and underlined
Tl.
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Figure 3.12: The results obtained from the two buffer SSCP/HD system
indicating the 4582_4589del polymorphic site
L1 L2
Lane 1: Individual with 4582_4589del
Lane 2: Control individual without deletion
Figure 3.13 : The results obtained from the automated sequencing in the
antisense direction of the PBGD gene fragment containing the 4582_4589del
8 bp deletion in a heterozygous individual
G i'. G {; :'~ G ; - .:»: G (:; C r ~:: w r: CT·. C i> /\: c c
210 .·:.L~.j ~.1::
The arrow indicates the location of the deletion in the antisense
orientation
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3.8.4 The 6479 G>T polymorphism in exon 10 of the PBGD gene
The CSGE screening method identified the 6479 G>T SNP in a 308 bp fragment
(See Table 3.12). This fragment contained exon 10 and the presence of the SNP
was confirmed with sequencing (See Figure 3.14). No restriction enzyme is
currently available to discriminate between the two alleles of this polymorphism.
The different allele frequencies of this SNP was found to be G=0.69 and T=0.31 in
a Caucasian group of 78 individuals, G=0.76 and T=0.24 in a group of 30 Afro-
Caribbean individuals and G=0.70 and T=0.30 in a group of 68 Africans (Robreau-
Froalini et al., 2000). Due to financial and time constraints this polymorphism was
not investigated in the extended VP group or the control group.
Table 3.12: The Partial gDNA sequence of the amplified region of exon 10 of
the PBGD gene indicating the 6479 G>T SNP. ( In the 5'-3' direction)
gggaaagaca gactcaggca gagggaaccg cacgaggccc cagattgccc
gacactgtgg tccttagcaa ctctccacag CGGGGAAACC TCAACACCCG
GCTTCGGAAG ATGGACGAGC AGCAGGAGTT CAGTGCCATC ATCCTGGACA
ACAGCTGGCC TGCAGCGCAT GGGCTGGCAC AACCGGGTTG GGCAGgtagg
gcctgcccct atcctctccc cagctcatct gcatctcctt tctgccttac
agtcatcccc aatttaggat ttttagactt tatgattgtg tgaaagcgat
atacgttca
Partial gDNA sequence obtained from gDNA sequence Accession number GI 292384. The exon 10
region is indicated by capital letters while the surrounding intron areas are given in lowercase letters.
The sequence of the forward primer and reverse primer are indicated in blue. The site of the 6479
G>T polymorphism is indicated with bold font and underlined
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Figure 3.14: The results obtained from the automated sequencing, in the
sense direction, of the PBGD gene fragment in a heterozygous individual
containing the 6479 G>T polymorphic site
C C GG G ':' KG G G Cl:" G G T 'fo, G
170 1
The arrow indicates the exact position of the 6479 G>T
polymorphism
A homology search of the human PBGD gene (GI 292384) and Rattus
norvergicus PBGD mRNA (GI 6981023) was conducted using the BLAST
program (http://www.ncbi.nlm.nih.gov/blast)(See Figure 3.15). The same
homology search was also performed for the human PBGD gene and the Mouse
porphobilinogen deaminase gene, exon 5 (GI 200229)(See Figure 3.15). The
area under scrutiny, exon 10 nt-6372 to nt-6498 of the human PBGD gene,
revealed significant homology with both the rat and mouse PBGD genes.
Sequence alignment analysis revealed that the rat PBGD gene 504 to 617
showed a 87% homology with the human PBGD gene nt-6372 to nt-6485, while
the PBGD gene of the mouse 402 to 528 had 86% homology with the human
PBGD gene nt-6372 to nt-6498.
The area surrounding the 6479 G>T polymorphism in exon 10 is conserved with
the G allele present in the rat and mouse sequence and the T allele present in
the human sequence. The high degree of conservation identified in these three
species probably points to the biological importance of the PBGD gene in the
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haem biosynthetic pathway and specifically this base position in a highly
conserved exon.
Figure 3.15: Sequence alignment of the human exon 10 region of the PBGD
gene with the rat PBGD mRNA and the mouse PBGD mRNA. ( In 5'-3'
direction)
Rattus norvegicus: (504)
Homo sapiens: (nt6372) (nt6431)
Mouse: (402 )
_.tgt,,_a ,,_.~
(617)Rattus norvegicus: (564)
Homo sapiens: (nt6432) aII•• aac4•• I9II••••• lcII•• I!IIU._ (nt6490)
Mouse: (462 ) g__ tgt ••• ~ •••••••• ;§IIc._. (520)
Homo sapiens: (nt6491) (nt6498)
(521) (528)Mouse:
Regions of homology with the human PBGD sequence are highlighted in purple. The G>T
polymorphism found in the human PBGD gene at position 6479 is highlighted in yellow.
3.8.5 The 7064 C>A polymorphism in intron 10 of the PBGD gene
The 213 bp fragment containing exon 11 was showed to habour a SNP (7064
C>A) when subjected to CSGE analysis (See Table 3.13). This was confirmed by
sequencing the fragment (See figure 3.16).
The restriction enzyme Hint I, cleaves the 213 bp fragment resulting in a 159 bp
and 54 bp fragment when the C allele is present. When the T allele is present
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there is no recognition site for the Hint I enzyme and therefore no cleavage of the
fragment (See Figure 3.17).
The allelic frequencies of the 7064 C>A polymorphism was reported to be C=0.75
and A=0.25 in a Caucasian group of 78 individuals (Robreau-Fraolini et a/., 2000)
and in a normal group of 92 American Caucasians (Yoo et aI., 1993). The 7064
C>A SNP was not investigated in the extended group of VP patients due to
financial and time constraints.
Table 3.13: Partial gDNA sequence of the amplified region containing exon
11 of the PBGD gene indicating the position of the 7064 C>A SNP
gaactcccat ctcactgcca ggtgctttta gacacccccg tgtccaccct
tttgact~cc tgttccgcct ccacagATCC TGCACCCTGA GGAATGCATG
TATGCTGTGG gCCAGgtaca cttgaccagg gaagccacat ggtgacatat
gccttccctt tgttctcaac caagaagctt gtctcacaac cttctgcatc
tgcttcccca gaa
Partial gDNA sequence obtained from gDNA sequence Accession number GI 292384. The exon
11 region is indicated by capital letters while the surrounding intron areas are given in lowercase
letters. The sequence of the forward primer and reverse primer are indicated in blue. The site of
the 7064 C>A polymorphism is indicated with bold font and underlined
Figure 3.16 : Results obtained from the automated sequencing in the
antisense direction of the PBGD gene fragment containing the 7064 C>A
polymorphic site in a heterozygous individual
GG A/\CAG G K !..,G T c : r\h 1\:lJC 4~
The arrow indicates the exact position of the 7064 C>A
polymorphism
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Figure 3.17: A 1.5% agarose gel demonstrating the Hint I restriction enzyme
cleavage of a 213bp product of intron 10 of the PBGD gene
159 bp
M L1 L2 L3 L4
213 bp
Marker:
Lanes 1, 3,4:
Lane 2:
100bp DNA ladder
Individuals homozygous for CC
Heterozygous individual TC
3.9 A comparison of the studied genes
Both the ALAS and PBDG enzymes are synthesized in duplicate forms, the
difference being, that ALAS is encoded by two separate genes, while PBGD is
encoded by a single gene that undergoes differential splicing. The two genes
encoding the human ALAS isoenzymes evidently evolved from a primitive
ancestral gene and their divergence resulted in different regulating domains (May
et al., 1990). Comparison of the Homo sapiens mRNA with the mRNA of the rat
showed that high conservation exists between species for the ALAS-1, ALAS-2
and PBGD genes. The ALAS-1 mRNA for the two species show 86% homology,
the mRNAs for ALAS-2 show 87% homology and the mRNAs for the PBGD gene
show 85% homology.
Among all the genes in the haem biosynthetic pathway, the PBGD gene has the
most identified mutations (Thunell, 2000). AlP caused by mutations in the PBGD
gene, is one of the porphyrias with the highest frequency. To date, sixteen
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polymorphic sites have been identified in the PBGD gene (See Table 1.4).
Thirteen are characterized as intragenie SNPs, one in an exon and two SNPs in
the non-erythroid promer region.
The ALAS-1 gene has no reported mutations and in the ALAS-2 gene only a few
mutations, causing X-linked sideroblastic anemia, have been identified (Human
gene mutation database; Krawczak and Cooper, 1997). To date 20 SNPs have
been identified in the ALAS-1 gene (Bio-chip: http://www.bio.chip.org /biotools/;
Locuslink: http://www.ncbi.nlm.nih. gov/SNP [Maglott et ai., 2000; Pruitt et ai.,
2000](See Table1.2). One SNP is located in the exonic area, eight are found in
the 5' untranslated region and eleven in the intronic areas. Eighteen SNPs have
been identified in the ALAS-2 gene (Bio-chip: http://www.bio.chip.org/biotools/;
Locuslink: http://www.ncbi.nlm. nih.gov/SNP [Maglott et ai., 2000; Pruitt et al.,
2000] (See Table 1.3). None of the identified SNPs are found in the exonic
areas, five of the SNPs are found in the 5'untranslated area, one SNP is found in
the 3' untranslated area and twelve SNPs are located in the intronic areas.
A homology comparison using the Homoloëene website
(http://www.ncbi.nlm.nih.gov/HomoloGene) revealed that all three genes
investigated (ALAS-1, ALAS-2 and PBGD) are greatly conserved among
species. The human ALAS-1 gene (UniGene Cluster: Hs.78712) shows 87.2%
ali9nment with the rat sequence (Uniqene Cluster: Rn 6274) and 87.2%
alignment with the mouse sequence (UniGene Cluster: Mm 19143). The human
ALAS-2 gene sequence (UniGene Cluster: Hs.323383) shows 99.7% alignment
with the rat sequence (UniGene Cluster: Rn 58391) and 87.9% alignment with
the mouse sequence (UniGene Cluster: Mm 140509). The human PBGD gene
sequence (UniGene Cluster: Hs 82609) shows 88.8% alignment with the rat
sequence (UniGene Cluster: Rn 11080) and 87.8% alignment with the mouse
sequence (UniGene Cluster: Mm 1710).
All this information supports the theory that these three genes are very important
in the haem biosynthetic pathway. The significance of the ALAs genes, known to
rate-limit the whole haem biosynthetic pathway is re-inforced by their
conservation, the lack of mutations and the presence of few SNPs. The ALAS
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genes may therefore be so important that mutations mau not be tolerated i.e.
they may be incompatible with life.
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Chapter Four
4 Conclusion
In the South African population, a high prevalence of VP exists due to a founder gene
effect (Meissner et al., 1996; Warnich et al., 1996). The majority of VP patients in
South Africa therefore have the same R59W mutation in the PPOX gene. However,
great variation in the clinical expression of the R59W patients is observed and even
members of the same family who would be expected to share a common genetic
background, and that have been exposed to similar environmental factors, exhibit great
clinical variation.
An attempt was therefore made to identify modifying factors that could contribute to the
clinical presentation of these individuals. The study population consisted of 25
individuals with the R59W mutation considered ideal for this study because the
contribution of the disease causing mutation could be ignored. The patients were
classified by a dermatologist and neurologist into four clinical groups. These clinical
groups consisted of a) asymptomatic individuals, b) individuals who had previous
symptoms of an acute attack (in clinical remission at time of study), c) individuals who
display skin symptoms, d) individuals who had both an acute attack and skin symptoms.
The distribution of the clinical symptoms found in our patients corresponded with the
results from previous studies done by Eales et al. (1980) and Whatley et al. (1999),
even though the number of our patients was relatively small. Although the current study
population is very small, a good foundation has been established for the clinical
classification of VP patients which will be very valuable in further studies concerning the
clinical expression of VP. It is thus suggested that more R59W patients be subjected to
the same established clinical classification process in order to assemble a larger VP
study group.
The rate of the entire haem biosynthetic pathway is determined by the activity of the
first enzyme ALA synthase, which is under negative feedback control by the free haem.
Secondary control is found at the level of PBG deaminase, which is inhibited by proto-
and coproporphyrinogen. The hypothesis is therefore that a mutation in the PPOX gene
in combination with a mutation in one of the rate limiting enzymes of the haem
biosynthetic pathway would cause a more severe phenotype. The ALAS-1, ALAS-2
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and PBGD genes were thus investigated for their possible modifying effect on the
clinical symptoms found in VP patients.
After comparing recent literature on the detection of sequence variation it was decided
to use two different SSCP techniques, one being a conventional method and the other a
method develop by Liechti-Galliti et al. (1999), entitled the two buffer SSCP protocol. In
combination with the two SSCP protocols a CSGE method was employed. The
conventional SSCP method was previously used in our laboratory, but the two buffer
SSCP protocol and the CSGE protocol were set up during this study. The CSGE
method had the highest success rate (83%), detecting 5 out of 6 sequence variants
identified during this study. The conventional SSCP method failed to identify 3 of the
sequence variants detected and the two buffer method failed to detect 4 of the
sequence variants. Both SSCP methods did, however, identify a SNP not detected by
the CSGE method. The SSCP methods only identified transition type SNPs and failed
to identify any transversion during this study.
Markoff et al. (1998) and Ganguly (2002) also found the CSGE method to be superior to
the SSCP method. We failed to detect 11 known SNPs (8 SNPs in the PBGD gene; 2
SNPs in the ALAS-1 gene and 1 SNP in the ALAS-2 gene), which in the case of the
ALAS-1 and ALAS-2 genes were published in December of 2001. The failure to detect
these SNPs could be due to either the frequency of these SNPs, that vary between the
populations in which they were described and the current study population, or the
location of the SNPs in the relevant PCR amplified fragment (See sections 3.6, 3.7 and
3.8). Primers can in future be redesigned to allow for a longer fragment between the
SNP and the end of the amplification product.
No variation detection technique developed to date has proven to have a 100%
sensitivity rate. Direct sequencing is still the superior method to use to identify
sequence variants, but is too expensive to use on a routine basis in the smaller
laboratory. The results of this study therefore indicate that two different techniques
(e.g. CSGE and conventional SSC!=» based on different principles are more successful
in identifying sequence variation than one method which could miss a sequence
variation due to the limitation of the relevant procedure.
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Six sequence variant sites (ALAS-1: 4713 T>C; PBGD: -64 C>T, 3581 A>G,
4582_4589del, 6479 G>T, 7064 C>A) were identified in the ALAS-1 and PBGD genes
using a screening population of 25 VP patients. Five of these variants were identified in
the PBGD gene. These five include four previously described polymorph isms and a
novel 8 bp deletion. One polymorphic site was identified in the ALAS-1 gene. No
sequence variation could be found in the ALAS-2 gene. Current literature indicates that
all three genes studied have the same amount of SNPs (See section 3.9). After the
investigation of the exon and the flanking intronic regions we speculate that the ALAS
genes may well be more conserved than the PBGD gene as we found more sequence
variation in the PBGD gene than in the two ALAS genes. More disease causing
mutations have also been identified in the PBGD gene than in the ALAS genes. The
conservation of the ALAS genes would coincide with the important regulatory function
these genes have to fulfill in the haem biosynthetic pathway.
Only two sequence variant sites were identified in exonic regions. The 4713T>C SNP
was found in exon 4 of the ALAS-1 gene and the 6479 G>T SNP in exon 10 of the
PBGD gene. The remaining four sequence variant sites were all identified in intronic
areas, except for the -64 C>T SNP in the 5' untranslated area of the PBGD gene.
Recent studies involving the successful identification of genetic modifying genes all
identified sequence variation in either an exon (Goldfarb et ai., 1992; Persu et ai., 2002)
or promoter region of a gene or in an intronic region where it was shown to influence
splice sites (Bala and Peltomaki. 2001; Chu et al., 1993; Gouya et ai., 2002). All six
sequence variants could not be tested in an extended group of VP individuals, due to
financial and time constrains. We therefore selected two sequence variant sites (ALAS-
1: 4713 T>C; PBGD: -64 C>T) due to their location in the respective genes. These
SNPs were tested in an extended group of 50 R59W VP patients (25 extensively
classified) and in a normal control group matched for ethnic background. Both of these
polymorphisms did not show any association of statistical significance with any of the
clinical groups. However, individual genetic modifying factors make a small contribution
to the total clinical picture and are therefore difficult to identify, even more so in a small
population. To rule out any possibility of association with one of the clinical groups, the
six sequence variant sites will need to be typed in future in a larger well-defined VP
patient group.
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The identification of modifier genes is further complicated by the involvement of
environmental factors in the disease progression. These difficulties are minimized in
animal models that allow for the extensive experimental control of both the genetic and
environmental variables. Recently researchers have developed a mouse model with
the R59W VP mutation and they are currently in the process of characterization. Urine
and faecal samples obtained from these mice indicate that they indeed have
biochemical abnormalities similar to those observed in human VP subjects (Medlock et
al., 2002). This mouse model could therefore prove very valuable in studies to identify
modifier genes that contribute to the clinical expression of variegate porphyria.
All the aims of this study as stated on page 36 have been met. However, due to the fact
that a limited number of individuals were available for this study, we could not prove any
positive association. Although we cannot prove our hypothesis until the sequence
variants are studied in a larger population, we can conclude that neither the 4713 T>C
in the ALAS-1 gene or the -64 C>T in the PBGD gene are probably a major locus
contributing to the clinical expression. In the event of these sequence variants being a
major locus we would most likely have detected association even in our small
population. This study did, however, provide insight into future investigational
strategies concerning these three important genes. Knowledge concerning these
genes could lead to a better understanding of the haem biosynthetic pathway and
ultimately to the understanding and assessment of the clinical expression found in VP
and other porphyrias.
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Appendix A
Variegate Porphyria
Clinical and Biochemical Data
I Name: I Maiden name: I Sex:
Admess: __
Telephone number: (H) (W)
I Date of Birth: I Age: I Origin:
Sun/light sensitivity (mark x)
Skin lesions (mark x)
Positive N~ative None
How frequently?
Biochemical test (mark x)
Acute attack (mark x)
Were you also tested for any other types of porphyria?
Postal code: Telephone number (W): __
Please complete to the best of your ability:
1.Medication:
Have you ever had anaesthesia administered ? _
Did you experience any problems while being under the anaesthetic or thereafter
?----------------------
Did you inform your anaesthetist that you or any members of your family are porphyria
suffers?--------------
Are you currently using any medication ?
-Contraceptives 0 name:
-Disprin 0 name:
o name: -----------------------o name: -----------------------o name: -----------------------
Have you ever used any of the above mentioned medications? -:--...,......, ,--- _
Did you show any reaction after these medications have been administered? -------------
2. Abdominal pain:
Have you ever been hospitalized for an acute attack ? _
Have you ever experienced serious bouts of abdominal pain? __
Could the cause be determined ?---------------------------------------
Specify / Describe the pain ---:----:- _
Do you regularly experience abdominal pain ? _
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3. Sun exposure
Is your work of such a nature that you are daily exposed to sunlight? _
Do you suntan? _-:-- __ -:-- _
Do you take precautions against sun exposure? _
4. Skin
Does your skin easily get hurt or bruised? _
Is your skin prone to form blisters or leave scars? _
Please specify: _
General:
Dark urine
Emotional disturbances
Constipation
High / low blood
pressure
Food sensitivity
Alcohol sensitivity
Iron supplements?
Iron related defects
Family history:
Porphyria
Multiple Sclerosis
Hemochromatosis
Other
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